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Adaptive immune responses against tumors are routinely detected in hosts bearing the tumors. 
However, the mechanisms of priming T cell responses which are central to the underlying 
immunosurveillance for nascent tumors remains unclear, given the limited amount of each 
unique tumor antigens available for cross-priming during the early stages of tumor development 
and lack of classical PAMPs in general. I provide evidence here that heat shock proteins (HSPs), 
when released into the tumor microenvironment under these conditions, is the molecular entity 
necessary for priming specific tumor-associated immunity. These responses require CD91, the 
endocytic and signaling receptor for the immunogenic HSPs. In this study, I generated CD11c-
specific CD91 knockout mice and showed that tumors grew faster in those knockout mice 
compared to CD91+/+ mice, due to a lack of priming efficient T cell responses. In addition, I 
abrogated the interaction of tumor-derived HSP with CD91 in vivo by over-expression of 
Receptor Associated Protein (RAP), an endogenous inhibitor of CD91. The data showed that: 
first, tumors expressing RAP grew with significantly faster kinetics than the non-RAP expressing 
counterparts in wild type mice, although this difference was non-existent in 
immunocompromised mice; second, RAP-expressing tumors, when used as an immunogen in 
tumor prophylaxis, were significantly less efficient in priming immune responses; third, 
inhibition of antigen cross-presentation by RAP reduced T cell proliferation in vivo; last, the 
THE ROLE OF HEAT SHOCK PROTEIN RECEPTOR CD91 IN INITIATION OF 
TUMOR-ASSOCIATED IMMUNITY 
 
Yu ‘Jerry’ Zhou, Ph.D. 
University of Pittsburgh, 2014
 
 v 
competition of RAP and tumor-derived HSP for binding to CD91 was examined in vivo. In the 
presence of RAP, fewer tumor-derived HSPs were taken up by APCs in draining lymph nodes. 
In summary, this study demonstrates that early in tumor development, the HSP-CD91 pathway is 
critical for establishment of anti-tumor immunity. Considering that elevated RAP levels have 
been reported in colon cancer patients, I propose a novel mechanism of immune evasion for 
tumors expressing competing ligands for immune receptors such as CD91. 
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1.0  INTRODUCTION 
1.1 TUMOR-ASSOCIATED IMMUNE RESPONSE 
1.1.1 Tumor immunosurveillance  
Cancer, the malignant form of a neoplasm, is the leading cause of death in developed countries 
and the second leading cause of death in developing countries  (Jemal et al., 2011). Despite 
inherent complexities, there are several essential alterations shared by the vast catalog of cancer 
cells that dictate their malignant growth, including self-sufficiency in proliferative signaling, 
insensitivity to growth inhibitory signals, evasion of cell death, replicative immortality, sustained 
angiogenesis, and tissue invasion/metastasis (Hanahan and Weinberg, 2000, 2011). Those 
genetic and cellular alterations provide the body's immune system with the means to resist or 
eradicate cancer cells. The long-standing theory of immunosurveillance proposes that normal 
cells or tissues are constantly monitored by the surrounding immune system and that such 
surveillance by immune cells leads to detection and elimination of most incipient neoplastic cells 
(or nascent tumors). This concept was first conceived by Paul Ehrlich (Ehrlich, 1909), and later 
formally proposed by Sir. Macfarlane Burnet and Lewis Thomas (Burnet, 1957; Burnet, 1970; 
Thomas, 1959).  
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With the advent of inbred mice, syngenic tumor cells, and genetic engineering, the 
hypothesis of immunosurveillance has been tested experimentally. Initially, experiments with the 
athymic nude mice showed discordant evidence against the immunosurveillance hypothesis, in 
that the incidence and development of MCA-induced tumor was similar between nude mice and 
their wild type counterparts (Stutman, 1974). However, certain caveats exist in these 
experiments. First, nude mice are not completely immunocompromised and still contain a 
detectable amount of αβ T cells, B cells, NK cells, etc. Second, the mouse strain used in 
Stutman's experiments is highly susceptible to MCA-induced tumors, and therefore rate of tumor 
formation in those mice may overwhelm the protection mechanisms by their immune systems. It 
was not until other immunocompromised murine models were made available in the 1980s and 
1990s, that the concept of immunosurveillance was resurrected. Mice deficient in various 
components of the immune system were, once again, examined for development of carcinogen-
induced tumors. The results showed that tumors arose more frequently and/or grew more rapidly 
in many immunocompromised mice compared to their immunocompetent controls (Dunn et al., 
2002; Schreiber et al., 2011). Specifically, impairment in development (e.g. rag2-/-) or function 
(e.g. Ifnr-/-, perforin-/-) of CD8+ cytotoxic T lymphocytes (CTL), CD4+ helper T cells, B cells, or 
Natural Killer (NK) cells each contributed to higher incidence of tumor (Engel et al., 1996; 
Engel et al., 1997; Girardi et al., 2001; Kaplan et al., 1998; Langowski et al., 2006; Liu et al., 
2004; Shankaran et al., 2001; Smyth et al., 2001; Smyth et al., 2000; Swann et al., 2007; Swann 
et al., 2009; Wakita et al., 2009). Mice with combined immunodeficiencies (e.g. rag2-/- γc-/-, 
RkSk mice) were even more susceptible to tumorigenesis (Shankaran et al., 2001). Additionally, 
a phenomenon called concomitant immunity provides further evidence that supports tumor-
associated immune responses. Coined by Paul Ehrlich, this concept describes a hypothesis that 
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the immune responses primed by a progressive tumor reject the second challenge of the same 
tumor at a distant site in the host (Ehrlich, 1906). It was later shown in murine models that a 
significant level of anti-tumor resistance against a later tumor challenge was not expressed until 
6 days after inoculation of the primary tumor, suggesting the involvement of adaptive immune 
responses (North and Kirstein, 1977).  
Immunosurveillance also plays a critical role in restraint of cancer in human patients. 
Several follow-up studies of individuals with primary immunodeficiency or transplant patients 
who were immunosuppressed showed that they have a significant higher risk of developing 
cancer (Gatti and Good, 1971; Penn, 1970; Vajdic and van Leeuwen, 2009). However, the vast 
majority of these cancers were virus-induced, suggesting that reduction of viral load was 
required to control tumorigenesis in these cases (Penn, 1999). But an increasing body of research 
has also recently demonstrated that, at least in some forms of non-virally-induced cancer, the 
immune system serves as a major barrier to tumor formation and development (Hoover, 1977; 
Penn, 1995, 1996; Pham et al., 1995; Sheil, 1986). In addition, studies suggest a positive 
correlation between infiltrated lymphocytes in a tumor and increased patient survival (Deligdisch 
et al., 1982; Epstein and Fatti, 1976; Lipponen et al., 1992; Nacopoulou et al., 1981; Naito et al., 
1998; Rilke et al., 1991). In summary, the data from mice and humans highlights the existence 
and significance of immunosurveillance. 
To elicit immune responses that eradicate cancer cells, a succession of events must be 
initiated and allowed to proceed iteratively, which is termed the ‘Cancer-immunity Circle’ (Chen 
and Mellman, 2013)(Figure 1-1). In the first step, neoantigens generated by tumorigenesis must 
be captured by surrounding antigen presenting cells (APCs). In order to activate APCs and 
downstream T cell responses, another alarming signal is generally required. These signals 
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include pathogen-associated molecular patterns (PAMPs) that are expressed by various classes of 
microbes, and danger-associated molecular patterns (DAMPs) that normally reside in the cells 
(step 1). APCs then process the neoantigen and present antigenic peptide on MHC I or MHC II 
to T cells in the context of costimulation (step 2), resulting in the priming of effector T cells (step 
3). The final outcome of immune responses is shaped in this stage, by a vital balance between 
effector T cells and regulatory T cells. Finally, the activated T cells traffic to (step 4) and 
infiltrate the tumor microenvironment (step 5), where they specifically recognize cancer cells 
expressing cognate antigen (step 6) and destroy the target cells (step 7). Killing of cancer cells 
leads to additional release of tumor-associated antigens (step 1 again), which then expand the 
breadth and depth of anti-tumor immunity.  
 
Figure 1-1 Cancer-immunity circle (Chen and Mellman, 2013) 
The cancer-immunity circle is a series of self-propagating events that amplify and broaden the antitumor immune 
responses. Schema of seven major steps in the circle is shown here, with the primary cell types involved and the 
anatomic location of different activities listed. (Reprinted from Immunity, Volume: 39, Chen DS and Mellman I, 
Oncology meets immunology: the cancer-immunity cycle, Pages 1-10, Copyright (2013), with permission from 
Elsevier) 
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Various types of APCs including macrophages and dendritic cells (DCs) serve as cellular 
sentinels in this cancer-immunity circle. While macrophages mainly serve as scavenger cells 
with greater capacity for antigen uptake, DCs possess superior antigen processing and 
presentation machinery (Delamarre et al., 2005). DCs represent a heterogeneous population with 
different morphologies, phenotypes and functions in various tissues (Merad et al., 2013; 
Steinman, 2012). There are two main subpopulations of DC: plasmacytoid DCs (pDCs) and 
conventional DCs (cDCs). pDCs morphologically resemble plasma cells but can produce 
enormous amounts of type-1 interferon (IFN) upon stimulation (Colonna et al., 2004). Recent 
data have indicated that tumors can induce type I IFN production possibly via pDCs, which is 
required for a spontaneous T cell response in vivo (Gajewski et al., 2012; Gajewski et al., 2013). 
cDCs refer to all DCs other than pDCs. Compared to pDCs, cDCs have an enhanced ability to 
capture, process, and present antigen to naive T cell responses, which are essential for tumor 
immunosurveillance (Joffre et al., 2012; Villadangos and Schnorrer, 2007). The surface marker 
CD11c is generally expressed in various subsets of cDCs, including CD8α+ DCs, Langerhans 
cells and CD103+ cells. However, CD11c+ cells are not limited to cDCs, since spleen 
macrophages, NK cells, activated T cells, and monocytes also express some level of CD11c 
(Merad et al., 2013). 
1.1.2 Tumor immuno-editing 
The repeated cancer-immunity circle is responsible for elimination of most nascent tumors. 
Immune system also sculpts the tumor cells in return. It has been proposed by Robert Schreiber 
that, in order to become clinically apparent, tumor cells need to undergo three ‘E’ phases of 
immune-editing---Elimination, Equilibrium, and Escape. The elimination phase corresponds to 
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immunosurveillance (Dunn et al., 2002).  In the equilibrium phase, tumor cells keep undergoing 
the selective pressure of immune destruction, become functionally dormant, and remain 
clinically unapparent for the life of the host. In the escape phase, cancer cells undergoing 
stochastic genetic and epigenetic mutation create critical modifications to avoid both innate and 
adaptive immunological destruction. Meanwhile, the immune system selects more aggressive 
tumor variants, and the immunologically sculpted tumor cells then grow unhindered, leading to 
appearance of overt cancer. Various forms of adaptation can be acquired by tumor cells to evade 
immunosurveillance (Rabinovich et al., 2007). On one hand, tumor cells can undergo cell-
autonomous modifications to avoid detection by professional antigen-presenting cells or 
destruction by effector immune cells; on the other hand, surrounding immune cells and stromal 
cells (Singh et al., 1992; Zhang et al., 2007) can be modified by tumors to generate a local 
immunosuppressive microenvironment.  
Tumor transplantation experiments provide strong evidence that support immunoediting. 
Cancer cells established in immunodeficient mice are significantly less efficient for generation of 
a secondary tumor when transplanted into the syngenic immunocompetent hosts. However, 
cancer cells that are harvested from immunocompetent mice are equally efficient in initiation of 
secondary tumor in both immunocompetent and immunodeficient hosts (Smyth et al., 2006). 
Those phenomena have been interpreted as follows: In the immunocompetent host, highly 
immunogenic tumor cells have been constantly targeted and eliminated by different mechanisms 
of immunosurveillance, leaving behind weakly immunogenic tumor variants, which survive this 
immuno-sculpting and keep growing to eventually generate solid tumors. When transferred, such 
weakly immunogenic tumors can therefore colonize both immunocompetent and 
immunodeficient secondary hosts. However, when arising in immunodeficient host, 
 7 
immunogenic tumor cells are not under pressure of immunoselection, and can therefore prosper 
along with their weakly immunogenic counterparts. When those nonedited tumors are 
transplanted into the syngenic recipient, the immunogenic cells will be rejected once they 
encounter a functional immune system of their secondary hosts for the first time. 
 
1.2 HEAT SHOCK PROTEINS AND THEIR IMMUNOLOGICAL PROPERTIES 
1.2.1 HSPs family, and their general functions 
Heat shock proteins (HSPs), the most abundant and ubiquitous soluble proteins inside the cell 
(Lindquist and Craig, 1988), can be classified into ten families, each consisting of one to five 
closely related proteins (Table 1-1). Under normal condition, HSPs represent up to 5% of the 
total intracellular proteins. However, their level can rise to 15% or more under stress, including 
high temperatures, toxins, and glucose deprivation. Since their discovery, an increasing number 
of various vital functions have been attributed to HSPs, such as molecular chaperones for protein 
folding and degradation (Gething and Sambrook, 1992; Parsell and Lindquist, 1993), building 
blocks of multi-subunit complexes (Haas, 1991), buffers of mutations (Queitsch et al., 2002; 
Rutherford and Lindquist, 1998), and mediator of thermotolerance (Lindquist, 1986). Additional 
studies also highlight the role of HSPs as a model in transcriptional regulation (Morimoto, 1998), 
stress responses (Lindquist, 1986), and molecular evolution (Feder and Hofmann, 1999). 
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Table 1-1. The major families of heat-shock proteins (Srivastava, 2002b) 
HSP family Members Intracellular location 
Small HSPs HSP10, GROES, HSP16, α-crystallin Cytosol 
  HSP20, HSP25, HSP26, HSP27   
HSP40 HSP40, DNAJ, SIS1 Cytosol 
HSP47 HSP47 Endoplasmic reticulum 
Calreticulin Calreticulin, Calnexin Endoplasmic reticulum 
HSP60 HSP60, HSP65, GROEL Cytosol and Mitochondria 
HSP70 HSP72, HSC70 (HSP73), HSP110/SSE, DNAK Cytosol  
  SSC1, SSQ1, ECM10  Mitochondria 
  GRP78 (BiP), GRP170 Endoplasmic reticulum 
HSP90 HSC84, HSP86, HTPG Cytosol 
  gp96 ( GRP94, HSP108, endoplasmin) Endoplasmic reticulum 
HSP100 HSP104, HSP110, CLP proteins Cytosol 
  HSP78 Mitochondria 
Reprinted by permission from Macmillan Publishers Ltd: Nature Review Immunology (Srivastava, 2002b), 
Copyright (2002) 
1.2.2 Immunological function of HSPs 
The immunological properties of HSPs were first discovered in the 1980s when homogenous 
fraction of tumor lysates containing HSPs elicited anti-tumor immune responses while same 
preparation of HSPs from normal tissue did not. The first studies were carried out with the HSP 
gp96 (Srivastava and Das, 1984; Srivastava et al., 1986; Ullrich et al., 1986). In subsequent 
years, this phenomenon was extended to hsp70, hsp90, calreticulin, hsp110, and grp170 (Basu 
and Srivastava, 1999; Tamura et al., 1997; Udono and Srivastava, 1993, 1994; Wang et al., 
2001). Interestingly, the HSPs purified from a certain type of cancer can only elicit protective 
immunity against that particular cancer. Where does this specificity come from? Extensive 
sequencing studies showed no difference of HSP cDNAs between cancers and normal tissues 
and from one cancer to another. Instead, the antigenic peptides associated with HSPs, which are 
generated as a result of normal protein turnover within cells, contribute to the specificity of 
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HSPs-mediated immunity (Srivastava et al., 1998). HSPs stripped off their chaperoned peptides 
lose their ability to mount measurable specific immune responses (Peng et al., 1997; Udono and 
Srivastava, 1993). HSPs chaperone peptides are comprised of the total pool of processed proteins 
within cells, including antigens derived from mutation (in transformed cells) or pathogen (in 
bacteria or virus-infected cells). Therefore, those peptides represent the antigenic fingerprint of 
the cells from which HSPs are purified.  
1.2.3 Mechanism of immunogenicity of HSPs 
A great amount of research has been conducted to investigate the cellular events that contribute 
to the immune responses following immunization with purified HSPs. Depletion of T cells or 
antigen presenting cells (APCs, such as dentritic cells or macrophages) abrogated immunity 
elicited by HSPs, suggesting that these cells play essential role for HSPs-mediated immune 
responses (Tamura et al., 1997; Udono et al., 1994). Considering that HSPs are intracellular 
proteins, their exposure in the extracellular environment was proposed to serve as a danger signal 
to alert APCs to stresses in the body, such as tumor necrosis (Basu et al., 2000; Somersan et al., 
2001). This proposal has been supported by two decades’ work of experimental investigations. 
When purified HSPs are used to interact with APCs, they are capable to elicit both adaptive and 
innate immune responses (Srivastava, 2002a, b) (Figure 1-2).  
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Figure 1-2. The interaction between HSPs and APCs integrate adaptive and innate immune events 
HSPs can engage APCs via their receptor CD91 to induce both adaptive and innate immune responses. On one hand, 
antigenic peptides chaperoned by HSPs are internalized, processed in the APCs, and presented on MHC I or MHC II 
to CD8+ T cells or CD4+ T cells. On the other hand, signals from HSPs can be relayed to nucleus, leading to 
activation and maturation of APCs. CD91 is both a scavenger receptor and a signaling receptor for HSPs, mediating 
downstream adaptive and innate immune responses. 
 
On one hand, HSP-peptide complexes are internalized into the APCs. After 
disassociation with HSPs, the antigenic peptides are then processed via different proposed 
pathways (Arnold-Schild et al., 1999; Basu et al., 2001; Castellino et al., 2000; Suto and 
Srivastava, 1995), and presented on the cell surface by MHC I or MHC II to T cells. On the other 
hand, once HSPs interacted with APCs, they can elicit downstream signal relay, which leads to a 
series of antigen nonspecific events that enhance immune responses. Those events include: (1) 
secretion of inflammatory cytokines; (2) induction of inducible nitric oxide synthase (iNOS) and 
production of nitric oxide; (3) secretion of chemokine; (4) maturation of dendritic cells indicated 
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by upregulation of MHC II, CD86, and CD40; (5) migration of dentritic cells from site of gp96 
injection to draining lymph node (Binder et al., 2000a); (6) nuclear translocation of 
transcriptional factor NF-kB (Pawaria and Binder, 2011; Srivastava, 2002a). Therefore, as a 
single entity, HSP-peptide complex is able to serve as antigen-carrier and adjuvant, and provide 
the dual signals of antigen and co-stimulation which are required for priming T cell responses.  
 
1.3 CD91: AN HSP RECEPTOR 
Typically, mice are immunized with 1-10μg of purified HSP-peptide complexes to prime a 
peptide specific T-cell response. This quantity of HSP-peptide complex contains less than 
nanogram levels of antigen-specific peptides. Instead, tens to hundreds of micrograms of 
peptides (with a conventional adjuvant) are usually needed to elicit a similar response. How can 
the small amounts of peptide chaperoned by HSPs be effective for immunization? Seeking an 
answer to this conundrum, Srivastava et al. first proposed, entirely on theoretical grounds, that 
HSP-peptide complexes must be targeted to a highly efficient pathway, possibly via cellular 
receptors (Srivastava et al., 1994). By utilizing various independent strategies, binding and 
competition studies showed that HSPs interacted specifically with APCs and could be titrated 
over a range of protein concentrations, supporting the notion of such a HSP receptor (Arnold-
Schild et al., 1999; Binder et al., 2000c; Wassenberg et al., 1999). 
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1.3.1 CD91 as a common receptor for HSPs 
To identify receptor(s) for HSPs, gp96 was immobilized on affinity columns and exposed to 
membrane protein extracts from APCs. An 85kDa protein that interacted with gp96 was isolated. 
In a parallel experiment, radiolabeled gp96 was tagged to short photoactivated cross-linkers, 
which extracted an 80KD molecule on the membrane of macrophage. The 10Å length of the 
cross-linkers indicated that the 80KDa molecule and gp96 closely interacted as a ligand and its 
receptor. Protein sequencing by mass spectrometry identified the 85kDa/80KDa molecule as a 
fraction of CD91 (Binder et al., 2000b). Although structurally unrelated, three other 
immunogenic HSPs, hsp70, hsp90, and calreticulin also utilize CD91 as a common receptor 
(Basu et al., 2001).  
CD91, also known as the α-2-macroglobulin (α2M) receptor and low density lipoprotein 
receptor-related protein 1 (LRP1), is expressed at least at the mRNA level in a variety of cell 
types, including myeloid cells, hepatocytes, hepatic stellate cells, neuronal cells, fibroblasts, 
adipocytes, adrenal cortical cells and follicular cells of the ovary. CD91 is translated as a single 
600kDa polypeptide and then proteolytically cleaved by a furin-like endoprotease into two 
subunits of 515kDa and 85kDa (Herz et al., 1990). The significance of this cleavage step is 
unknown, although it may not be critical for its endocytic functions (Ko et al., 1998). The large 
extracellular α-subunit of 515kDa contains 4 ligand-binding clusters that can bind to a wide 
variety of unrelated ligands including ApoE-containing lipoproteins, lipoprotein lipase, 
complexes of proteinase-proteinase inhibitors, growth factors, and hormone. The α-subunit is 
non-covalently linked to the 85kDa β-subunit, which contains a small extracellular portion, a 
single-span transmembrane domain and a short cytoplasmic tail with two tyrosine 
phosphorylation (NPXY) motifs (Herz and Strickland, 2001). (Figure 1-3) 
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The role of CD91 in priming immune response is two-fold: First, CD91 is a scanvager 
receptor. Blocking of CD91 via an anti-CD91 antibody, or its ligands such as α2M, can abrogate 
the cross-presentation of peptides chaperoned by the HSPs (Basu et al., 2001).  Second, CD91 
also serves as a signaling receptor. Once it interactes with HSPs, CD91 is phosphorylated in a 
unique pattern, which triggers signaling cascades to activate NF-kB. Each type of HSP induces a 
unique cytokine profile via CD91, which dictates priming of specific T-helper cell subsets 
(Pawaria and Binder, 2011). 
 
The aforementioned immunlogical role of HSP-CD91 interaction was established based 
on several biochemical (by using anti-CD91 antibody) and genetic evidence (by using siRNA for 
Figure 1-3 Subunits and ligand-binding 
clusters on CD91 (Herz and Strickland, 
2001) 
 
CD91 ligands can bind to the different 
clusters of ligand-binding repeats on its α-
subunit. majority of the CD91 ligands bind 
to the Cluster II and IV. Cysteine-rich 
ligand-binding repeats (red ovals) are 
arranged in four clusters containing 2, 8, 
10, and 11 repeats, respectively. Each 
cluster is followed by 1-4 EGF homology 
domains (blue), which consist of cysteine-
rich EGF repeats (blue circles) and YWTD 
domains (wavy line). Two NPxY motifs in 
the cytoplasmic tail of β-subunit are 
indicated by the asterisks. Copyright 
(2001) American society for clinical 
investigation 
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CD91)(Banerjee et al., 2002; Binder et al., 2000b; Binder and Srivastava, 2004; Habich et al., 
2002; Ling et al., 2007; Robert et al., 2008; Stebbing et al., 2003). In order to validate protein 
function in vivo, knockout mouse models have been a gold standard in recent two decades, 
although they are time consuming and lab intensive. There are certain caveats associated with 
these models. For example, the pleiotropic effects caused by various requirements for a 
particular gene in different locations, or at different stages of embryonic development may 
complicate the analysis. In the case of CD91, attempts to generate a conventional knockout 
mouse failed due to an early embryonic lethal phenotype (Herz et al., 1992; Herz et al., 1993). 
As an alternative, the Cre/LoxP-mediated recombination system is able to overcome these 
hurdles, by targeting genes in a temporally- or spatially-specific way. Indeed, successful tissue-
specific inactivation of CD91 in brain, liver, and vascular smooth muscle cells using this 
approach have been reported in different functional studies (Boucher et al., 2003; May et al., 
2004; Rohlmann et al., 1998; Rohlmann et al., 1996). The structure of the 'floxed' allele is shown 
in Figure 2-1. Cre-mediated recombination is expected to cause deletion of part of promoter, 
transcription start site, exon I encoding the signal peptide, and exon II, therefore rendering the 
allele truncated and untranscribable.  
1.3.2 Other molecules proposed to be HSP receptors 
The discovery of CD91 as a HSP receptor opened the floodgates in the following years for 
describing additional HSP receptors in several cases, but with controversial evidence. These 
include: lectin-like oxidized LDL receptor-1 (LOX-1), Toll-like receptor 2/4 (TLR2/4), CD14, 
CD40, Scavenger receptor-A (SR-A), and Scavenger receptor expressed by endothelial cell-1 
(SREC-1). The experimental evidence for and against each of them is summarized in Table 1-2. 
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Table 1-2 Evidence for and against possible candidates for HSP receptor [adapted from (Binder, 2009)] 
Proposed receptor Ligands Supporting data Discordant data 
CD91 Gp96 
HSP70 
HSP90 
Calreticulin 
 (1) Physical association of HSPs and 
CD91; 
 
(2) Competitive binding of other 
CD91 ligands or antibodies; 
 
(3) Internalization of HSP-peptide 
complexes; 
 
(4) Inhibition of cross-presentation 
and signal transduction by CD91 
siRNA, site-mutation on β-chain of 
CD91, or anti-CD91 antibodies; 
 
(5) In vivo abrogation of HSP-
mediated immunity with anti-CD91 
antibodies. 
(1) CD91-independent binding of 
HSPs. One caveat is that cells used in 
this assay lack sufficient fixation; 
 
(2) ‘Cross-presentation’ of HSP-
chaperoned peptides is CD91-
independent. However, it is shown 
later that peptides used in this study 
can be directly presented on MHC I. 
LOX-1 HSP70 Binding and competition studies with 
other CD91 ligands and antibodies. 
No data supporting physical 
interaction 
TLR2/4 HSP70 
HSP60 
Gp96 
HspB8 
α-Crystallin 
HSP-induced cytokine secretion or 
NF-kB activation was inhibited in 
APCs pulsed with anti-TLR2/4 
antibodies, or in APCs with dominant 
negative MyD88 or deficient in 
TLR2/4 
(1) Issues of endotoxin contamination 
have not been addressed. 
 
(2) No data supporting physical 
interaction 
CD14 HSP60 
HSP70 
(1) Human astrocytoma cells 
transfected with cDNA for CD14 
were able to secret cytokine in 
response to HSP; 
 
(2) Cytokine released by APCs 
pulsed with HSPs was inhibited by 
anti-CD14 antibodies  
(1) Issues of endotoxin contamination 
have not been addressed. 
 
(2) No contribution of CD14 in HSP 
binding assay. 
 
(3) No data supporting physical 
interaction. 
 
CD40 HSP70 (1) Binding and competition studies 
with other CD91 ligands and 
antibodies; 
 
(2) Internalization of HSP/peptide. 
 (1) Studies examining physical 
interaction were conducted with 
recombinant (non-native) proteins; 
 
(2) The consequences of mammalian 
HSP70-APC interaction were 
identical in kinetics and magnitude 
between CD40+/+ and CD40-/- mice. 
SR-A Gp96 
Calreticulin 
(1) Binding and competition studies 
with other CD91 ligands and 
antibodies; 
 
(2) Partial cross-presentation of HSP-
peptide complexes. 
(1) Issues of endotoxin contamination 
have not been addressed. (SR-A 
binds to LPS) 
 
(2) In vivo data did not demonstrate a 
role for SR-A in HSP-mediated 
immunogenicity; 
 
(3) No data supporting physical 
interaction 
SREC-1 Gp96 
Calreticulin 
Binding and competition studies with 
other CD91 ligands and antibodies. 
(1) In vivo data suggested that SREC-
I did not function in HSP binding; 
 
(2) No data supporting physical 
interaction 
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In order to verify the identity of those molecules as a HSP receptor, four major issues 
need to be addressed. First, purity of HSP preparation is a major caveat in all the experiments 
where recombinant HSPs purified from bacteria were used, especially with regards to 
contamination with bacterial endotoxin (e.g. LPS). The LPS receptor TLR2/4 and its co-receptor 
CD14 have been suggested as HSP receptors in some studies, where deficiency or blockade of 
these molecules or their downstream adaptors inhibits the activation of APCs (Asea et al., 2002; 
Vabulas et al., 2002a; Vabulas et al., 2002b). However, it was later shown that HSP-mediated 
immune responses in the above experiments were indistinguishable from those induced by 
endotoxin (Bausinger et al., 2002; Gao and Tsan, 2003). Therefore, extra caution needs to be 
taken when using recombinant HSPs to identify their receptor; second, even if the amount of 
exdotoxin in recombinant HSPs was below detection level, those HSPs may lack proper post-
translational modification such as glycosylation or add molecular tags such as glutathione S-
transferase (GST) or myc, both of which may interfere with ligand-receptor interaction or 
introduce artificial binding. Instead, use of proteins as close to their physiological state as 
possible such as purified endogenous HSPs under the guideline of the Good Laboratory Practice 
(GLP) * provide a solution to both prevent endotoxin contamination and maintain a much more 
natural pattern of protein modification and folding; third, most candidates of HSP receptors have 
been proposed based on the competitive binding or activation assays of APCs in vitro. However, 
few of them have been concluded from direct evidence of physical interaction between ligand 
and receptors; fourth, because of the caveats mentioned above, verification in vivo is required. 
Unfortunately, with the exception of SR-A (which turned out not to have a role in vivo) and 
CD91, none of the other HSP receptor candidates have been examined via in vivo assay.  
 
*: Good Laboratory Practice or GLP refers to a quality control system for research laboratories to ensure the 
uniformity, reliability and consistency of data generated in non-clinical experiments (W.H.O, 2009). 
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1.4 RAP, AN ENDOGENOUS ANTAGONIST FOR CD91 
Receptor associated protein (RAP) is a three domain 40kDa protein, which functions as 
an escort protein for receptors of low-density lipoprotein receptor (LDLR) family, including 
CD91. It helps post-translational processing of CD91, prevents premature intracellular binding of 
ligands, and assists with delivery of mature CD91 to the cell surface (Bu, 1998). By using 
immunoelectron microscopy to examine cells that robustly express RAP such as U87 cells and 
HepG2 cells, RAP was localized most abundantly within the endoplasmic reticulum (ER, 70%) 
and Golgi compartment (24%) with only 4% in the endosomes and 2% on the cell surface (Bu et 
al., 1994). Cells expressing RAP include, but are not limited to, CD91-expressing cells [Data 
from the Immunological Genome Project (www.immgen.org)].  
RAP is known to bind with high affinity to CD91 and therefore prevents other ligands 
from binding to CD91 (Bu et al., 1992; Herz et al., 1991; Warshawsky et al., 1993). Other than 
CD91, no molecules have been shown to interact with RAP. The mechanisms by which RAP 
inhibits the binding and uptake of CD91 ligands are not completely understood. However, 
previous studies suggested that RAP may bind to all ligand-binding sites on CD91, and that each 
of these RAP binding sites on CD91 may be recognized by various binding determinants on RAP 
itself. In the case of HSPs, studies in vitro demonstrated that their binding to CD91 was also 
blocked by RAP, which also inhibited cross-presentation of chaperoned peptides (Figure 
1-4)(Binder and Srivastava, 2004). Interestingly, no apparent structural similarities were 
observed between RAP and HSPs. These results led to the idea that the elevated levels of RAP 
released from necrotic tumor cells in vivo could potentially inhibit immunogenicity of HSPs 
derived from the same tumor.  
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Figure 1-4  RAP inhibited the binding of HSPs to CD91 and blocked cross-presentation of chaperoned 
peptides in vitro. Figure adapted from (Binder and Srivastava, 2004)  
(A) RAP competed with gp96 for binding to CD91+ macrophage RAW264.7 cells. Paraformaldehyde (PFA)-fixed 
RAW264.7 cells were incubated with FITC labeled gp96 (gp96-FITC) with or without increasing amount of 
unlabeled competitors including RAP. Unbound protein was removed by extensive washing. The cells were then 
analyzed by flow cytometry. The mean fluorescence intensity was measured as an indication of the amount of bound 
gp96-FITC. Here I highlighted that increasing the amount of RAP (red square) decreased the amount of gp96-FITC 
bound to cells. (B) The same study examined whether cross-presentation of gp96-chaperoned peptides was inhibited 
by RAP. Gp96 was complexed to AH1-19, a 19mer peptide containing an Ld-restricted epitope. Gp96-AH1-19 was 
incubated with the APC RAW264.7 and a CD8+ T cell clone that recognized with Ld/AH-1 in a 20 hour re-
presentation assay. Stimulation of the CD8+ clone was measured by secretion of IFN-γ by the T cells. Again I 
highlighted here that increasing the amount of RAP inhibited re-presentation of gp96-chaperoned peptides. 
Copyright (2004) National Academy of Sciences, USA. 
 
1.5 OUTLINE OF THIS THESIS DISSERTATION 
The dual roles of HSPs as both an antigen carrier and an adjuvant in one entity make them a 
good candidate which can initiate tumor-associated immunity efficiently. Therefore, in this thesis 
dissertation, I examine the requirement of HSP-CD91 pathway in immunosurveillance against 
tumor. Since HSPs are essential for the survival of cells, depletion of HSPs is not possible. 
Instead, I target and selectively delete their common receptor CD91 in mice. Chapter 2 of this 
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thesis describes the generation and characterization of such CD91 conditional knockout mice, 
and studies whether loss of CD91 expression in APCs affects tumor-associated immunity.  
CD91 possess both immunological and non-immunological functions. It is not known 
whether loss of CD91 expression mainly affects uptake of antigen, compromises the ability of 
APC to cross-present antigen in general, or both. Chapter 3 of this thesis directly examines the 
requirement of ligand-binding ability of CD91 for anti-tumor immunity by over-expression of 
RAP.  
It is also important to show that HSPs are the ligands that bind to CD91 or are inhibited 
by RAP. Therefore, Chapter 4 of this thesis highlights the competition of RAP and tumor-
derived HSP for binding to CD91. There, I utilize a strategy to label HSP gp96 with Enhanced 
Green Fluorescent Protein (EGFP) and co-transfected gp96-EGFP with RAP or a control protein 
into different tumor cells, so that the localization and trafficking of this fluorescent-labeled gp96 
can be monitored in vivo.  
The results obtained in Chapter 2-4 are further discussed in Chapter 5. Some future 
directions and the implication of data on the current theory of cancer immunosurveillance and 
immunoediting are considered. 
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2.0  LOSS OF CD91 EXPRESSION IN APCS ABROGATES TUMOR-ASSOCIATED 
IMMUNITY 
2.1 RATIONALE 
In a majority of patients with cancer and in murine experimental tumor systems, recognition of 
the tumor by the host’s immune system occurs, resulting in priming of concomitant immunity 
and immunoediting (North and Kirstein, 1977; Schreiber et al., 2011; Shankaran et al., 2001). 
Conventional mechanisms of priming immune responses to pathogens do not generally apply to 
tumors because, wherever tested, tumors generally lack sufficient antigen, as a native soluble 
protein, for cross-priming (Binder and Srivastava, 2005). In addition, being of self origin, tumors 
in a sterile environment lack the classical PAMPs to activate innate signals and co-stimulation 
necessary for priming T cells. Given the ability of endogenous, purified HSPs to efficiently 
prime specific immune responses under conditions of limiting antigen (Binder and Srivastava, 
2005; Srivastava et al., 1986), I tested the role of tumor-derived HSPs in situ and their receptor 
CD91 in initiation of immune responses to tumors.  
 
I have explored the HSP-CD91 axis as a mechanism for host priming of anti-tumor 
immunity for two reasons; i) antigens in the form of peptides are chaperoned by HSPs and are 
efficiently cross-presented by APCs (Binder et al., 2007; Blachere et al., 1997; Matsutake et al., 
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2010; SenGupta et al., 2004; Suto and Srivastava, 1995). The increase in efficiency of cross-
presentation of HSP-chaperoned peptides versus peptides or whole antigen protein alone, is 
several thousand fold and is made possible through the cell surface receptor CD91 on antigen 
presenting cells (Basu et al., 2001; Binder et al., 2000b; Binder and Srivastava, 2004, 2005; 
Tischer et al., 2011; Tobian et al., 2004), and ii) our lab has recently shown that HSPs signal 
through CD91 and activate APCs for co-stimulatory capacity based on secretion of pro-
inflammatory cytokines, including IL-1β, TNF-α, IL-6 and up-regulation of CD40, MHC II and 
CD86 molecules (Basu et al., 2000; Chen et al., 1999; Pawaria and Binder, 2011; Wang et al., 
2002). These observations explain the ability of six intracellular HSPs, gp96, hsp90, hsp70, 
calreticulin, hsp110 and grp170 to prime immune responses, specific for the peptides they 
chaperone in cells, once they have been purified from various antigen-bearing cells including 
tumors and pathogen-infected cells (Basu et al., 2001; Basu and Srivastava, 1999; Binder et al., 
2000b; Blachere et al., 1997; Mo et al., 2011; Navaratnam et al., 2001; Srivastava et al., 1986; 
Tamura et al., 1997; Udono and Srivastava, 1993; Wang et al., 2001; Zugel et al., 2001). 
 
The immunological properties of HSPs make them prime candidates for the initiation of 
immune responses to tumors. However, HSPs are necessary for survival of cells, so testing their 
requirement for priming tumor-specific immune responses in vivo through simultaneous or 
sequential deletion is not possible. Instead, I test their requirement by targeting and selectively 
deleting the HSP receptor, CD91, in mice. This approach is possible because while structurally 
unrelated, four of the abundant and immunogenic HSPs, gp96, hsp90, hsp70 and calreticulin, 
utilize the common receptor CD91 to elicit their immune responses (Basu et al., 2001; Binder, 
2009; Binder et al., 2000b; Binder and Srivastava, 2004; Pawaria and Binder, 2011). I show that, 
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unlike wild type mice, mice lacking CD91 expression on dendritic cells fail to elicit tumor-
associated immunity. 
2.2 MATERIALS AND METHODS 
2.2.1 Mice 
B6;129S7-Lrp1tm2Her/J (CD91flox/+) mice (Jackson Laboratory, Bar Harbor, ME) were mated to 
homozygousity. CD91 conditional knockout mice were generated by crossing B6.Cg-Tg(Itgax-
cre)1-1Reiz/J (CD11c-Cre) mouse with CD91floxP/flox mouse. Specific depletion of CD91 in 
CD11c+ cells was confirmed by using immunoblot and flow cytometry. All experiments with 
mice were approved by the Institutional Animal Care and Use Committee (Pittsburgh, PA) and 
performed in compliance with its guidelines. 
2.2.2 Cells and reagents 
Tumor cell lines; lung carcinoma D122 and Simian Virus 40 (SV40)-induced SVB6 were 
obtained from American Type Culture Collection and cultured in complete Dulbecco’s modified 
Eagle’s medium (DMEM), which includes 1% sodiumpyruvate, 1% L-glutamine, 1% non-
essential amino acids, 1% penicillin and streptomycin, 0.1% 2-mercaptoethanol and 10% fetal 
bovine serum (GIBCO). All tumor cell lines were free of specific pathogen, tested by IMPACT I 
PCR Profile (Research Animal Diagnostic Laboratory, RADIL, Columbia, MO). All cell cultures 
were maintained at 37˚C in a humidified atmosphere containing 5% CO2. 
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Ovalbumin 8mer peptide (SIINFEKL) was synthesized by Genemed Synthesis Inc (San 
Antonio, TX). Complete Freund's adjuvant, incomplete Freund's adjuvant, and LPS were 
purchased from Sigma (St. Louis, MO). GM-CSF was purchased from Fisher Scientific. Mouse 
CD8α+ T cell isolation kit, and mouse CD11c microbeads were purchased from Miltenyi Biotec 
(Auburn, CA). Mouse IL-1β ELISA kit and mouse IL-2 ELISA kit were purchased from 
eBioscience (San Diego, CA). Pacific Blue anti-mouse CD8α antibody, PerCP-Cy5.5 anti-mouse 
CD4 antibody, APC anti-mouse CD19 antibody, PE-Cy5 anti-mouse CD3 antibody, PE anti-
mouse CD11c antibody, PE-Cy7 anti-mouse CD11b antibody, FITC anti-mouse CD40 antibody, 
PE anti-mouse CD86 antibody, and PE anti-mouse MHC II (I-A/I-E) antibody were purchased 
from BD Pharmingen. Anti-CD91 β-chain antibody and anti-CD8 depleting antibody were 
purified from culture supernatant of 11H4 and TIB210 hybridomas (ATCC), respectively.  
2.2.3 Tumor rejection assay after HSP vaccination 
In the E.G7 tumor system, gp96 was purified from cultured cells as previously described 
(Srivastava et al., 1986). Mice were immunized intradermally with 1µg gp96 twice one week 
apart and challenged with 5x105 E.G7 tumor cells in saline one week later. Tumor growth was 
measured on two axes and expressed as average tumor diameter. 
 
2.2.4 Tumor growth assay 
8x105 D122 or 1x106 SVB6 tumor cells were injected intradermally in CD91-/- or control mice, 
with or without CD8 depletion. Tumor growth was measured on two axes thereafter. CD8 T cells 
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were depleted with anti-CD8 antibody one day before tumor challenge as previously described 
(Sayles and Johnson, 1996). 
2.2.5 CD91 independent T cell priming 
CD91-/- and CD91+/+ mice were immunized subcutaneously with 20µg OVA 8 peptide 
emulsified in Freund's adjuvant at an interval of one week. One week after the last vaccination, 
5x106 splenocytes were harvested from OVA 8 peptide immunized CD91-/- or CD91+/+ mice, and 
cultured ex vivo for 5 days in the presence of OVA 8 peptide. Specific T cell responses were 
monitored by IL-2 ELISA. 
2.2.6 T cell proliferation assay in vivo. 
OT-1 cells were harvested from spleens, enriched for CD8+ T cells (Miltenyi Biotec), and 
labeled with CFSE (Invitrogen). CFSE-labeled OT-1 cells (2.5x106 cells per mouse) were 
transferred to CD91-/- or CD91+/+ mice via the retro-orbital route. One day later, recipient mice 
were immunized intradermally with 20 μg OVA 8 peptide emulsified in Complete Freund's 
adjuvant. After 3 days, cells from draining lymph nodes were harvested and stained with anti-
CD8 antibody. CFSE dilution of the previously transferred OT-1 cells was examined. 
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2.2.7 Statistical analysis.  
An unpaired two-tailed Student's t-test or two-way ANOVA test was used for statistical analyses, 
and a P value of less than 0.05 was considered statistically significant. Error bars were calculated 
as standard error of the mean (s.e.m). 
2.3 RESULTS 
2.3.1 Creation and characterization of CD11c-specific CD91-/- mice 
Using multiple approaches in vitro, our lab and others have demonstrated that CD91 serves as a 
receptor for immunogenic HSPs including gp96 (Basu et al., 2001; Binder et al., 2000b; Binder 
and Srivastava, 2004; Pawaria and Binder, 2011; Tischer et al., 2011; Tobian et al., 2004). 
Conventional CD91 knock-out mice are embryonically lethal (Herz et al., 1992; Herz et al., 
1993), thus I created mice lacking CD91 expression in CD11c+ cells, to test the role of CD91 for 
HSP-mediated immunogenicity in vivo.  
Mice with homozygous floxed CD91/LRP1 (CD91flox/flox) were crossed with mice 
expressing Cre-recombinase under the CD11c promoter. Expression of Cre in CD11c+ cells 
cause site-specific recombination of lox sequence, which deleted part of promoter, transcription 
start site, exon I, and exon II of CD91 (Figure 2-1 A). Members of the F1 generation were then 
back-crossed with the homozygous CD91flox/flox parent and confirmed CD91flox/flox CD11c Cre+/- 
offspring were mated for all subsequent generations (Figure 2-1 B-D).  
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Figure 2-1 Creation of CD11c-specific CD91-/- mice 
(A) Schema showing positions of the LoxP sites which occur prior to transcription starting site and at the end of 
exon 2 of cd91. Position of Forward (Abbreviated as 'F') and Reverse (Abbreviated as 'R') primers are also shown, 
adding a 59bp size to the PCR product. (B). Mating scheme for CD11c specific CD91 KO mice is shown. (C). 
Representative genotyping of CD91flox/flox is shown and compared to heterozygote CD91flox/- (Het.) and wild type 
littermate mice. (D) Representative genotyping of CD11c Cre+/- is shown. This assay will not distinguish 
hemizygous from homozygous transgenic animals. The 313bp band corresponds to the Cre transgene, and the 200bp 
band corresponds to an internal positive control. 
 
Lack of CD91 expression was confirmed in BMDCs of these mice, generated by 
culturing bone marrow cells in GM-CSF for 6 days (Inaba et al., 1992). CD11c+ cells were 
purified with magnetic beads to 96% purity. Cells were analyzed by SDS-PAGE and 
immunoblotting for CD91 protein expression (Figure 2-2 A). In addition, CD11c+ cells in the 
lymph nodes of CD91flox/flox Cre+/- mice were analyzed by flow cytometry. Loss of CD91 
expression in CD11c+ cells was confirmed (Figure 2-2 B). The CD11c+ cells from the lymph 
node analyzed in Figure 2-2 B included Langerhan’s cells, CD103+ cells and other subsets of 
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dendritic cells. Loss of CD91 expression thus occurred on all these cellular subtypes in CD91-/- 
mice, regardless of their conceivable role in HSP-dependent immunity.  
 
Figure 2-2. CD91 expression is lost in CD11c+ cells 
CD91flox/flox mice were mated with CD11c+-Cre recombinase mice and backcrossed. (A) BMDCs were sorted for 
CD11c to 96% purity and analyzed by immunoblotting for CD91 β-chain or actin as a loading control. (B) Lymph 
node cells from CD91-/- (blue) or CD91+/+ littermates (black) were stained with anti-CD91 antibody, gated on 
CD11c+ and analyzed by flow cytometry. Filled grey is secondary antibody alone. Experiments were independently 
performed twice with 2 mice per group. 
2.3.2 Selective loss of CD91 in CD11c+ cells renders mice unresponsive to gp96 
These mice, herein referred to as CD91-/-, had normal percentages of other cellular 
immune compartments including CD4 and CD8 T cells, B cells, macrophages and DCs when 
compared to litter mates, CD91flox/flox Cre-/- mice (CD91+/+) (Figure 2-3 A). The ability of 
BMDCs from CD91-/- mice to mature was tested by pulsing these cells with LPS for 24 hours 
and monitoring the expression of several maturation markers. CD86, CD40 and MHC II were all 
up-regulated in response to LPS, and the up-regulation was to similar levels as the BMDCs from 
CD91+/+ littermates (Figure 2-3 B). BMDCs from CD91-/- mice were also able to respond to LPS  
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Figure 2-3. Selective loss of CD91 in CD11c+ cells renders mice unresponsive to gp96 
(A) Lymph node cells from CD91-/- or CD91+/+ littermates were phenotyped for markers indicated. (B) BMDCs 
from CD91-/- or CD91+/+ mice were pulsed on day 6 with LPS for 24 hours (black line) or left un-pulsed (blue line). 
Cells were analyzed for expression of CD86, CD40 and MHC II. Filled grey is secondary antibody alone. (C) 
BMDCs from CD91-/- (blue line) or CD91+/+ (black line) mice were pulsed on day 6 with 100μg gp96 for 24 hours or 
left un-pulsed (filled grey). Cells were analyzed for expression of CD86 and CD40. (D) BMDCs from CD91-/- or 
CD91+/+ mice were pulsed with 100μg gp96 or 1EU LPS for 24 hours or with PBS. IL-1β was measured by ELISA. 
* P< 0.05, ** P< 0.01, n.s. not significant. Error bars indicate s.e.m. Experiments were independently performed 
twice with 2 mice per group. Representative data from 1 mouse was shown in (A-C). 
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by secreting IL-1β, measured by ELISA 24 hours later (Figure 2-3 D). Importantly however, 
CD91-/- BMDCs failed to secrete IL-1β in response to gp96. Control BMDCs from CD91+/+ mice 
secreted IL-1β after stimulation with LPS or gp96, consistent with previous observations (Basu 
et al., 2000; Pawaria and Binder, 2011). Additionally I tested the ability of BMDCs to mature in 
response to gp96 as previously shown (Messmer et al., 2013). BMDCs from CD91-/- mice failed 
to upregulate maturation markers CD86 and CD40 in response to incubation with gp96 (Figure 
2-3 C). BMDCs from CD91+/+ were able to do so. 
I next tested the response of CD91-/- mice to gp96 immunization in a prototypical tumor 
rejection assay (Binder and Srivastava, 2004; Srivastava et al., 1986). CD91-/- or CD91+/+ mice 
were immunized with E.G7-derived gp96. Mice were then challenged with E.G7 and tumor 
growth was monitored. While tumors were rejected in the gp96-immunized CD91+/+ mice (as 
routinely observed, Binder and Srivastava, 2004; Srivastava et al., 1986), the rejection was 
absent in the gp96-immunized CD91-/- mice (Figure 2-4). 
 
Figure 2-4. CD91-/- mice fail to respond to HSP vaccination 
CD91-/- or CD91+/+ mice were immunized with 1 µg E.G7 tumor-derived gp96 twice, one week apart, followed by 
E.G7 tumor challenge one week later. Tumor growth was monitored. ** P< 0.01. Error bars indicate s.e.m. 
Experiments were independently performed twice with 3-5 mice per group. 
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2.3.3 Loss of CD91 expression in antigen presenting cells abrogates tumor-
associated immunity 
As a measure of tumor-associated immunity, I tested the rate of growth of tumors in CD91-/- 
mice using the moderately immunogenic tumor D122, a highly metastatic clone of the 3LL 
(Lewis Lung) carcinoma. When mice were inoculated with 8x105 D122 cells, tumor growth rate 
was significantly faster in CD91-/- mice versus CD91+/+ recipient mice (Figure 2-5 A). The 
significant difference in tumor growth rate was observed at early time points, up to day 11, with 
differences then dissipating. To test the role of the adaptive immune response on tumor growth, I 
depleted CD8+ T cells from the CD91-/- or CD91+/+ mice. When CD8+ cells were depleted, D122 
tumors grew with identical kinetics in mice from both groups (Figure 2-5 B). The rate of tumor 
growth in both groups was identical to CD91-/- mice in Figure 2-5 A. Therefore, specific CD8+ T 
cell priming was impaired in CD91-/- mice. To test the generality of these observations, similar 
experiments were performed with the highly immunogenic, regressor SV40-transformed tumor 
SVB6. While SVB6 cells ultimately grew and were rejected in both the CD91-/- and CD91+/+ 
mice, the tumors grew significantly larger and were rejected more slowly in CD91-/- mice (Figure 
2-5 C).  
Since CD91-/- mice were deficient in their ability to mount anti-tumor immune responses, 
I tested their general immuno-competence by priming with a regimen that bypasses a 
requirement for antigen uptake and intracellular processing. CD91-/- or CD91+/+ mice were 
immunized with the OVA 8-mer (SIINFEKL) peptide plus Freund’s adjuvant and spleen cells 
were examined for T cells specific for the peptide. The peptide used, OVA 8, required no uptake 
or further processing by APCs prior to binding MHC I. Following peptide stimulation of spleen 
cells ex vivo, IL-2 was measured in cultures by ELISA as an indication of OVA 8-specific T cells 
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(Figure 2-6 A). Equitable levels of functional responsive OVA 8-specific T cell responses were 
obtained in either type of mouse (P = 0.5428, Figure 2-6 B). I used a second read out to confirm 
the results in Fig. 2D. CFSE-labeled OT-1 cells were adoptively transferred into CD91-/- or 
CD91+/+ mice one day prior to immunization with OVA 8 peptide plus adjuvant (Figure 2-6 C). 
Three days later, lymph nodes were harvested and percent dividing OT-1 cells was quantified. 
No difference in the percent of dividing OT-1 cells was observed between immunization of 
CD91-/- and CD91+/+ mice (Figure 2-6 D). These result are consistent with normal immune 
phenotype observed in Figure 2-3 and shows that CD91-/- mice are capable of priming T cell 
responses when immunized with peptide + adjuvant, a regimen that does not require CD91 for 
uptake.  
 
Figure 2-5. CD91 expression in CD11c+ cells is required for tumor-associated immunity. 
(A) CD91-/- or CD91+/+ littermates were challenged intradermally with D122 tumor cells. Tumor growth was 
measured on two axes. (B) CD8+ cells were depleted from CD91-/- or CD91+/+ mice 24 hours prior to implantation of 
intradermal D122. CD8 depletion was continuous for >5 days. Tumor growth was monitored as in (A). (C) SVB6 
tumor was implanted intradermally into CD91-/- or CD91+/+ littermates. Tumor growth was monitored as in (A). n.s., 
not significant; * P< 0.05. Experiments were independently performed twice with 3-5 (A,C) or 2 (B) mice per group. 
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Figure 2-6. CD91-/- mice are not grossly immunocompromised. 
(A) Schema for CD91 independent priming. CD91-/- or CD91+/+ mice were immunized with OVA8 peptide 
(SIINFEKL) emulsified in CFA (week 1) or IFA (week2). Supernatants from spleen cells cultured ex vivo with 
OVA8 peptide for 5 days were analyzed for IL-2. (B) IL-2 ELISA was performed on supernatant of cultures. (C) 
CFSE-labeled OT-1 cells were transferred to mice followed by immunization with OVA8 peptide in CFA. Lymph 
nodes were harvested on day 3. (D) Percent dividing OT-1 cells in lymph nodes were measured by flow cytometry. 
n.s, not significant. Experiments were independently performed twice with 3-5 mice per group. 
2.4 DISCUSSION 
In this chapter, I generated CD11c-specific CD91 conditional knockout mice, and showed that 
mice deficient in the receptor CD91 on CD11c+ antigen presenting cells became unresponsive to 
gp96, and were unable to mount substantial immune resistance to tumors, in the form of a CD8+ 
T cell response. To my knowledge, these findings are the first reports of a direct role for CD91 in 
priming tumor-associate immunity in vivo. I have taken advantage of my development of a novel 
system where the tumor and elicitation of tumor-associated immunity can be left unperturbed by 
experimental manipulation in vitro.    
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By using immunoblotting and flow cytometry, loss of CD91 expression was confirmed in 
CD11c+ cells derived from CD91-/- mice, although residual level of CD91 can still be observed in 
those cells (Figure 2-2). This residual signal may come from contaminating cells such as 
macrophages, because it was technically unfeasible to get a higher purity of CD11c+ cells than 
96% by using MACs isolation in my experiment. Additionally, the expression of Cre is 
dependent on the promoter of the cd11c gene. Therefore, cells that weakly express CD11c may 
also have a low level of Cre recombinase. In those CD11clowCrelow cells, CD91 expression may 
not be completely abrogated. However, the loss of CD91 expression was significant, since anti-
tumor immune response was inhibited in these CD91-/- mice when compared to CD91+/+ mice.  
I conducted several studies to examine the phenotype of these newly-generated CD91-/-
mice, including percentages of cellular immune compartments, and maturation of CD91-/- 
BMDC. BMDCs were used because significantly more CD11c+ cells were required for this 
experiment than could be obtained from lymph nodes. BMDCs express a similar phenotype as 
DC in vivo, including the CD11c+ marker (Lutz et al., 1999). The characterization continues 
unabated, in the immunological and non-immunological realm, however all the experiments that 
are relevant for my hypothesis in this project have been performed. Importantly, unlike WT 
BMDCs, BMDCs from CD91-/- mice failed to upregulate maturation marker and secrete 
cytokines in response to HSP gp96. However, CD91-/- BMDCs were still able to respond to a 
alternative maturation stimulus LPS. This result supported previous findings from our lab and 
others that CD91 serves as a bona fide receptor for four major immunogenic HSPs including 
gp96.  
Besides CD91, several other receptors have also been suggested to be involved in HSP-
mediated signaling and activation of APCs, such as TLR2/4. The involvement of TLR2/4 as HSP 
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receptors was based on a series of studies in which cells transfected with TLR2 and/or TLR4 
became responsive to recombinant HSPs, as measured by NF-kB activation or release of 
cytokines/chemokines. These immune effects were reduced in cells from knockout mice that lack 
TLR2/4 or their downstream adaptors MyD88 or TRAF-6, or cells incubated with anti-TLR2/4 
antibodies (Asea et al., 2002; Vabulas et al., 2002a; Vabulas et al., 2002b). However, as 
mentioned in the Introduction (refer to chapter 1.3.2), the recombinant HSPs used in these 
studies were contaminated with bacteria-derived endotoxins such as LPS, which also use TLR2/4 
as a receptor. Therefore, loss of TLR2/4 or their downstream adaptors actually abrogated 
immune response induced by contaminating LPS, but not HSPs per se. Although removal of LPS 
was attempted in some studies by using polymyxin B beads, residual amount of LPS may still 
remain in the bacteria-derived recombinant HSPs. In the presence of gp96, TLR ligands such as 
LPS have been shown to activate DC even at a low concentration (<1 ng/ml). However, TLR 
ligands alone were unable to activate DC at this concentration (Warger et al., 2006).  
I also compared kinetics of tumor growth between CD91-/- mice and their wild type 
littermates. My data demonstrated that tumors proliferated faster in these knockout mice, 
possibly due to impaired priming of CD8+ T cells. Interestingly, the significant difference in 
tumor growth rate was observed only at early time points, up to day 11. The disparity dissipated 
thereafter. It suggested that CD91-independent mechanisms may come into play to restrict tumor 
growth when tumor volume increases significantly. Therefore, the relatively large amount of 
inoculated tumor cells (8x105 D122 used in this case) should be factored in to explain the short-
lived impact of CD91 deficiency on tumor growth. Fewer tumor cells will be inoculated in future 
experiments to examine the importance of CD91 for extended duration before tumors become 
firmly established. 
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When CFSE-labeled OT-1 cells were used to examine the capacity of CD91-/- and 
CD91+/+ mice to prime immune responses after peptide plus adjuvant treatment, I observed that, 
although the percentage of dividing OT-1 cells was similar, OT-1 cells divided more completely 
in CD91+/+ mice compared to CD91-/- mice (data not shown). It suggested that, besides antigen 
uptake, CD91 may play a role in enhancement of T cell proliferation.  
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3.0  LIGAND-BINDING ABILITY OF CD91 IS REQUIRED FOR ANTI-TUMOR 
IMMUNITY 
3.1 RATIONALE 
CD91 exerts both immunological and non-immunological functions. Its α-chain can bind to an 
array of ligands, which participates in several physiological functions, such as lipoprotein 
metabolism and transport, cell migration, clearance of protease and neurotransmission. As shown 
in the previous chapter, CD91 is required to control tumor growth, possibly via priming of CD8+ 
T cell responses. However, the precise role of CD91 in this process is still unknown. CD91 may 
be required for ligand endocytosis, signaling, antigen presentation, T cell priming, etc. Both ex 
vivo assay on cytokine secretion and in vivo assay on  T cell proliferation in previous chapter 
showed no difference between CD91-/- and CD91+/+ mice, suggesting that antigen presentation 
and downstream T cell priming remain intact in the knockout mice. In this chapter, I then 
directly examined ligand-receptor interaction for CD91 and its influence on antigen presentation 
and anti-tumor immune responses. 
RAP is a 40-KDa molecular chaperone of CD91, which assists delivery of CD91 from 
ER to cell surface and prevents premature binding of other ligands during membrane trafficking. 
The reason why it blocks access of other structurally and functionally distinct ligands to CD91 is 
that RAP can bind to all four ligand-binding domains on CD91 with high affinity. Indeed, 
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previous studies in vitro showed that RAP competed away HSPs from binding to CD91 and 
inhibited downstream cross-presentation of HSP-chaperoned antigenic peptides (Figure 1-3). It is 
therefore a powerful tool to introduce RAP in vivo to scrutinize the importance of ligand-binding 
ability of CD91 on antigen-transfer and tumor-associated immune responses. To this end, I 
transfected different tumor cell lines with RAP-expressing vector. In the event that tumor cells 
lose their membrane integrity, I hypothesized that RAP would be released concurrently with 
HSPs and therefore prevent HSPs from binding to CD91 on surrounding APCs.  
In this chapter, I transfected different tumor cell lines with RAP plasmid, and 
demonstrated that tumors expressing RAP grew with significantly faster kinetics than the non-
RAP expressing counterparts in wild type mice, although this difference was non-existent in 
immunocompromised mice. Inhibition of antigen transfer and downstream cross-presentation by 
RAP abrogates T cell proliferation in vivo, and therefore decrease the immunogenicity of tumors. 
3.2 MATERIALS AND METHODS 
3.2.1 Mice.  
Female BALB/c, C57BL/6, C.129S7(B6)-Rag1tm1Mom/J (rag1-/- BALB/c), and B6(Cg)-
Rag2tm1.1Cgn/J (rag2-/- C57BL/6), C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1), B6.SJL-
PtprcaPepcb/BoyJ (CD45.1) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) 
and housed in the animal facility at the University of Pittsburgh. All experimental mice were 6–
8-weeks old. All experiments with mice were approved by the Institutional Animal Care and Use 
Committee (Pittsburgh, PA) and performed in compliance with its guidelines.  
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3.2.2 Cells and Reagents.  
Tumor cell lines; fibrosarcoma CMS5 and Simian Virus 40 (SV40)-induced SVB6 were obtained 
from American Type Culture Collection (ATCC) and cultured in complete Dulbecco’s modified 
Eagle’s medium (DMEM), which includes 1% sodium pyruvate, 1% L-glutamine, 1% non-
essential amino acids, 1% penicillin and streptomycin, 0.1% 2-mercaptoethanol and 10% fetal 
bovine serum (GIBCO). RAP or control vector-transfected tumor cells were cultured in complete 
DMEM media plus blasticidin (3µg/mL, Invitrogen). All tumor cell lines were free of specific 
pathogen, tested by IMPACT I PCR Profile (Research Animal Diagnostic Laboratory, RADIL, 
Columbia, MO). All cell cultures were maintained at 37˚C in a humidified atmosphere 
containing 5% CO2. Ovalbumin, complete Freund's adjuvant, incomplete Freund's adjuvant, 
LPS, and mitomycin-C were purchased from Sigma (St. Louis, MO). GM-CSF was purchased 
from Fisher Scientific. Ovalbumin was rendered free of endotoxin by detoxi-Gel columns 
(Thermo Scientific). Mouse CD8α+ T cell isolation kit, and mouse CD11c microbeads were 
purchased from Miltenyi Biotec (Auburn, CA). APC anti-mouse CD45.2 was purchased from 
BD Pharmingen. Anti-V5-HRP antibody, 53kDa V5-containing protein (positope) was 
purchased from Invitrogen (Carlsbad, CA).  Anti-hsp90 antibody were purchased from Enzo Life 
Sciences (Farmingdale, NY).  
3.2.3 Plasmid construction and transfection.  
Total RNA was prepared from mouse liver by using the RNeasy Mini Kit (Qiagen, ON, Canada) 
and treated with RNase-free DNase to eliminate any potential genomic DNA contamination.  
Aliquots of 1μg of total RNA were used to synthesize first-strand cDNA by using the Omniscript 
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RT kit (Qiagen, ON, Canada). The cDNA was amplified to generate full-length RAP and short-
length RAP which lacks the N-terminal signal sequence, by the following primer pairs 
respectively: (1) GAGATGGCGCCTCGAAGAGAGA (RAP-NT1) and 
GAGTTCATTGTGCCGAGCCCTTGA (RAP-CT); (2) GAGATGGGTTACT 
CGCGAGAGAAGAA(RAP-NT2) and GAGTTCATTGTGCCGAGCCCTTGA (RAP-CT). 
PCR amplification was performed by using 2X Mango Mix (Bioline USA Inc, MA) for initial 5 
cycles (94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min) and additional 25 cycles (94°C for 
30 sec, 65°C for 30 sec, and 72°C for 1 min). After amplification, the PCR products were 
inserted into pEF6/V5-His-TOPO vectors (Invitrogen), which were then transformed into One 
Shot® TOP10 chemically competent Escherichia coli (Invitrogen, Carlsbad, CA). CMS5 and 
SVB6 tumor cells were stably transfected with each of the plasmids by using Fugene® 6 
transfection reagent (Roche Molecular Biochemicals). DNA sequencing was performed at 
Genewiz or at the Genomics and Proteomics Core Laboratories at the University of Pittsburgh. 
3.2.4 Tumor growth assay  
To test the effect of RAP on immunogenicity of tumors, BALB/c (or C57BL/6) mice were 
challenged with 1x106 RAP- or control vector-transfected CMS5 (or SVB6) cells. In a separate 
experimental setting, immunocompromised rag1-/- BALB/c or rag2-/- C57BL/6 mice were 
challenged with 1x106 corresponding RAP- or control vector-transfected tumor cells. Tumor 
growth was measured on two axes for 2-3 weeks after challenge.  
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3.2.5 In vitro proliferation assay 
The in vitro proliferative rates of those tumors were determined by the Click-iT EdU Assay Kit 
(Invitrogen, Carlsbad, CA).  
3.2.6 Tumor rejection assay  
To test antigen transfer from RAP-expressing tumor cells to APCs, BALB/c mice were 
immunized intradermally with titrated dose of mitomycin C-treated, RAP- or control vector-
transfected CMS5 cells. Two weeks later, mice were challenged with 1x106 untransfected CMS5 
cells. Tumor growth was measured on two axes thereafter.  
3.2.7 T cell proliferation assay in vivo.  
Endotoxin-free OVA was introduced to CMS5 cells expressing RAP or control protein control 
by electroporation at 200 V for 30 ms (Bio-rad). The OVA-loaded cells were then rendered 
replication incompetent by treatment with mitomycin-C. CD45.2+ OT-1 cells were harvested 
from spleens, enriched for CD8+ T cells (Miltenyi Biotec), and labeled with CFSE (Invitrogen). 
CFSE-labeled OT-1 cells were transferred to CD45.1+ C57BL/6 or CD91-/- mice via the retro-
orbital route (1.5x106 cells per mouse; total OVA in these cells is <1 ng). One day later, recipient 
mice were immunized intradermally with 1x105 replication-incompetent OVA-transfected CMS5 
with or without RAP expression. After 3.5 days, cells from draining lymph nodes were harvested 
and stained with anti-45.2 and anti-CD8 (for the experiment in CD45.1+ C57BL/6 mice, Fig. 5 D) 
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and anti-CD8 antibody only (Fig. 5 E) to enrich for the previously transferred OT-1 cells. CFSE 
dilution of those OT-1 cells was examined.  
3.2.8 Microscopy  
Transfected tumor cells were cultured overnight in 35 mm glass bottom culture dishes (MatTek 
Corp. Ashland, MA) at 37°C, washed with PBS, fixed in 2% paraformaldehyde, permeabilized 
in 0.1% Triton X-100, and blocked with 2% BSA. For RAP transfected cells, mouse anti-V5 
antibody and Cy3-conjugated goat anti-mouse IgG antibody were used to stain RAP; rat anti-
HSP90 antibody and DyLight488-conjugated goat anti-rat IgM antibody were used to stain 
HSP90; DAPI was used to stain nucleus. For gp96-EGFP transfected cells, rhodamine 
conjugated Phalloidin (Invitrogen/Life Technologies, Grand Island, NY) was used to stain 
cytoskeleton; DAPI was used to stain nucleus, according to a protocol developed by the Center 
for Biologic Imaging (CBI, University of Pittsburgh). Tumor tissues were incubated with 2% 
paraformaldehyde for one hour, then with 30% sucrose at 4°C overnight. After freezing, tumor 
tissues were cut into 8um thick sections using a cryo-microtome (HM505E Microm). The 
sections were permeabilized with 0.1% Triton X-100 and blocked with 2% BSA. Mouse anti-V5 
antibody and Cy3-conjugated goat anti-mouse IgG antibody were used to stain RAP. Rat anti-
HSP90 antibody and DyLight488-conjugated goat anti-rat IgM antibody were used to stain 
HSP90. DAPI was used to stain nucleus. All images were captured using an Olympus FV1000 
inverted confocal microscope with 100x objective (Fig. 3 C and D, and 6 B) or 60x objective 
(Fig. 3 K) and Fluoview v. 2.1 acquisition software (Melville, NY). Imaris v. 7.2.1 (Bitplane, 
Zürich, Switzerland) and Photoshop v. 7.0 (Adobe, San Jose, CA) were used for analysis and to 
prepare the images for publication.  
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3.2.9 Statistical analysis.  
An unpaired two-tailed Student's t-test or two-way ANOVA test was used for statistical analyses, 
and a P value of less than 0.05 was considered statistically significant. Error bars were calculated 
as standard error of the mean (s.e.m). 
3.3 RESULTS 
3.3.1 CD91-HSP interaction is required for priming anti-tumor immunity 
To determine if abrogation of ligand binding to CD91 was responsible for the decreased immune 
responses to tumors (seen in Fig 2), I constructed two types of plasmids: (1) plasmid expressing 
wild type RAP, and (2) plasmid expressing modified short-length RAP, which lacks its N-
terminal signal sequence necessary for ER translocation (Figure 3-1 A). Unlike wild type RAP 
which is expressed in the endoplasmic reticulum, modified RAP will be expressed in the cytosol. 
The rationale behind expressing a cytosolic version of RAP is that I can still study the effect of 
elevated RAP levels on tumor immunity even if only plasma membrane, but not ER membrane, 
loses its integrity in some physiological setting. Indeed, the result from experiments in this 
chapter showed a greater inhibitory effect of the cytosolic RAP compared to its wild type 
counterparts (data not shown). Therefore, I present data based on cytosolic RAP thereafter.  
The cDNA of RAP was amplified by PCR and inserted into pEF6/V5-His-TOPO vectors, 
in which RAP and a V5 tag were expressed under a strong promoter PEF-1a (Figure 3-1 B). I then 
expressed and quantified RAP in the moderately immunogenic fibrosarcoma CMS5, or SVB6 
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(Figure 3-2). Tumors were determined to express ~10 fg of RAP per cell for both tumors. 
Tumors transfected with RAP was then stained with anti-V5 antibody representing RAP, and 
anti-HSP90 antibody as a marker for cytosol. Fluorescent microscopy observed co-localization 
of the stains for RAP and HSP90, indicating the cytosolic expression of RAP (Figure 3-3). 
 
 
Figure 3-1. RAP is expressed under a strong promoter PEF-1a 
(A) Full-length RAP cDNA (1083bp) and short-length RAP cDNA (978bp) were cloned from murine hepatocytes. 
(B) Full-length or short-length RAP, in tandem with a V5 tag, was expressed by the pEF6/V5-His-TOPO vector, 
under a strong promoter PEF-1a. 
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Figure 3-2. Quantification of stable RAP 
expression in tumor cells. 
 
The CD91 inhibitor, RAP, was transfected 
and stably expressed in tumor cells, as 
confirmed by immunoblot in CMS5 cells 
(A), or SVB6 cells (B). Titrated amount of 
a 53 kDa V5-expressing protein was 
blotted and scanned to obtain relative 
optical density (OD). (D and E) a linear 
relationship was established between the 
titrated amounts of the V5-expressing 
protein and their relative OD. (B) and (D) 
were used to quantify RAP expression in 
CMS5 cells. (C) and (E) were used to 
quantify RAP expression in SVB6 cells. 
The relative OD values of CMS5 and 
SVB6 bands (2x106 cells equivalent) were 
5091 and 8162, respectively. Experiments 
were independently performed twice. 
Figure 3-3. RAP is expressed in the 
cytosol of tumor cells. 
 
Cytosolic localization of RAP in CMS5 
(A) cells, or SVB6 (B) cells was examined 
by confocal microscopy comparing the 
signal of RAP with the cytosolic protein 
HSP90. The two signals co-localized to 
give the yellow color. Experiments were 
independently performed twice. 
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Tumors expressing RAP or a control (non-CD91 binding) protein were then implanted 
into BALB/c mice and tumor growth was monitored. In the tumor growth assay, RAP-expressing 
CMS5 grew with significantly faster kinetics when compared to control CMS5 tumor cells 
(Figure 3-4 A). However, when the same tumor cells were implanted into immunocompromised 
rag1-/- mice, there was no difference in growth rate between the RAP and non-RAP expressing 
tumor cells (Figure 3-4 B). Since tumor growth rate is determined largely by the balance between 
tumor cell proliferation and lysis (mediated in part by immune effectors), I tested if RAP 
transfection had any effect on cellular proliferation. There was no difference in growth rate 
between RAP and non-RAP expressing cells when tested in a proliferation assay in vitro that 
measured incorporation of EdU dye into DNA (Figure 3-5 A-B). These results were confirmed in 
the SVB6 tumor system in C57BL/6 mice. RAP-expressing SVB6 tumors grew to a significantly 
bigger size and were rejected more slowly than control SVB6 tumor cells (Figure 3-4 C). In 
immunocompromised rag2-/- mice, however, the growth of tumors was comparable irrespective 
of RAP expression (Figure 3-4 D). Similar to the CMS5 model, SVB6 tumors proliferated 
comparably in vitro whether they expressed RAP or not (Figure 3-5 C). The reduction of 
immunogenicity of RAP-transfected cells depends on the continual expression of RAP. 
Therefore, RAP expression in tumors was monitored throughout the duration of the experiment 
and was found to be preserved 15 days after implantation (Figure 3-6). These results highlight 
the role of CD91 as a receptor for ligand binding, in mounting tumor-associated immunity. 
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Figure 3-4. Inhibition of ligand binding to CD91 abrogates priming of anti-tumor immunity 
(A and B) CMS5 cells expressing RAP or a control protein were implanted intradermally in BALB/c (A) or rag1-/- 
(B) mice and tumor growth was monitored. Average tumor diameter was calculated. (C and D) SVB6 cells 
expressing RAP or control protein were implanted into C57BL/6 (C) or rag2-/- (D) mice and tumor growth was 
monitored. * P < 0.05, ** P < 0.01. Experiments were independently performed thrice with 3-5 mice per group. 
Error bars indicated s.e.m. 
 
 
Figure 3-5. The inherent proliferative rates of tumors with or without RAP are identical. 
(A). The Click-iT EdU Flow Cytometry Assay Kit from Invitrogen was used for the in vitro proliferation assay.  It 
directly measures DNA synthesis in S phase, similar to the BrdU assay. (B-C) Proliferation of CMS5 cells (B) or 
SVB6 (C), with RAP or control protein expression, was determined by EdU incorporation into DNA. n.s., not 
significant. Experiments were independently performed twice. Error bars indicated s.e.m. 
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Figure 3-6. RAP expression is maintained throughout the tumor growth assay. 
CMS5 tumor expressing RAP were established intradermally in BALB/c mice for 15 days. Tumor was harvested, 
sectioned and stained with antibodies to V5-tagged RAP and cytosolic HSP90. Experiments were independently 
performed twice. 
 
3.3.2 RAP abrogates antigen transfer in vivo and inhibits T cell priming 
To examine the transfer of antigen from tumor cells to APCs in the presence or absence of RAP 
in vivo, I rendered the transfected tumor cells replication incompetent and used them as a source 
of antigen. Mice were immunized with titrated doses of replication-incompetent CMS5 tumor 
cells expressing RAP or control protein (Figure 3-7 A). Two weeks later, the mice were 
challenged with 1x106 wild type CMS5 cells and tumor growth was monitored. No protection 
was seen at the 1,000 immunizing dose in either group (Figure 3-7 B). However, when mice 
were immunized with 10,000 cells, RAP-expressing cells failed to protect mice from a 
subsequent tumor challenge while the control tumor cells were able to elicit protection (Figure 
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3-7 C). These results are consistent with RAP-expressing cells failing to transfer their antigen to 
APCs leading to inefficient cross-priming of T cells. At >1x105 immunizing cells, tumor cells 
expressing either protein were able to protect mice suggesting that at higher antigen doses, 
CD91-independent mechanisms for antigen transfer to cross-prime APCs may come into play 
(Figure 3-7 D and E).  
 
 
Figure 3-7. RAP abrogates antigen transfer in vivo and inhibits T cell priming. 
The ability of RAP-expressing CMS5 to transfer antigen and prime immune responses was tested in a tumor 
prophylaxis assay. (A) Schema showing the experimental design, in which BALB/c mice were immunized with 
titrated doses of replication incompetent, RAP-expressing cells and later challenged with parental (wild type) CMS5 
cells. (B-E) Mice were immunized with 1000 (B), 10,000 (C), 100,000 (D) or 1,000,000 (E), RAP or control protein 
expressing CMS5 tumor cells rendered replication incompetent. Mice were challenged with 1x106 parental CMS5 
cells in all groups and tumor growth was measured. * P < 0.05, ** P < 0.01. Experiments were independently 
performed twice with 3-5 mice per group. Error bars indicated s.e.m. 
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3.3.3 Inhibition of antigen cross-presentation by RAP reduces T cell proliferation 
in vivo. 
Upstream of anti-tumor responses, I tested the ability of RAP to prevent antigen transfer by 
measuring levels of antigen presented to T cells in the draining lymph nodes. CFSE-labeled 
CD45.2+ OT-1 cells were adoptively transferred into naïve mice (CD45.1+) which were 
immunized a day later with 1x105 ovalbumin-loaded CMS5 tumor cells (Figure 3-9 A). This 
number of cells was estimated to be loaded with a total of approximately 1 ng of ovalbumin 
(Figure 3-8). The ovalbumin-loaded CMS5 tumor cells either expressed RAP or a control 
protein. The CMS5 tumor is of the H-2d haplotype and cannot directly present the OVA8 peptide 
to OT-1 cells. Therefore stimulation of the OT-1 cells will be an indication of cross-presentation 
by resident APCs of the (H-2b, CD45.1+) C57BL/6 mouse. Lymph node cells were harvested 
after 3 days and the percent of dividing CD8+CD45.2+ cells was determined by flow cytometry. I 
show CFSE dilution in OT-1 cells from representative mice in Figure 3-9 B and C. In multiple 
mice (Figure 3-9 D) I show that the presence of RAP in the tumor cells accounted for a decrease 
in proliferation of OT-1 cells when compared to cells expressing a control protein. This is despite 
the fact that both cell types were loaded with exactly the same amount of OVA. In parallel 
experiments, CFSE-labeled OT-1 cells were transferred into CD91-/- mice one day prior to 
immunization with replication incompetent, ovalbumin loaded CMS5 cells (Figure 3-10). CMS5 
cells were expressing RAP or an irrelevant protein. Lymph node cells were harvested after 3 
days and the percent of all dividing CD8+ cells was determined by flow cytometry. Regardless of 
RAP expression, no OT-1 proliferation was observed in these CD91-/- mice. When mice were 
immunized with 10 times more OVA loaded CMS5 cells (1x106, 10 ng), no difference was 
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observed in dividing OT-1 cells when cells expressed RAP or a control protein (Figure 3-11). 
This latter result was consistent with results in Figure 3-7 D,E when antigen doses are high. 
 
 
Figure 3-8 The amount of ovalbumin protein loaded in CMS5 cells 
(A) Titrated amount of ovalbumin protein and 2x106 cell equivalent (c.e.) of lysate from OVA-loaded CMS5 were 
analyzed by SDS-PAGE and immunoblotted with anti-OVA antibody. The immunoblots were scanned and 
quantified, and the relative optical density (OD) units are indicated below the blots. (B) A semi-quantitative 
relationship was established between the titrated amounts of ovalbumin protein and their relative OD. It was 
established that 1x105 cell immunizing dose contained approximately 1 ng of OVA. 
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Figure 3-9. Inhibition of antigen cross-presentation by RAP reduces T cell proliferation in vivo. 
The effect of RAP on T cell proliferation in vivo was examined. (A) CD45.1+ C57BL/6 mice were adoptively 
transferred with CFSE-labeled CD45.2+ OT-1 cells (1.5x106 per mouse), one day before immunization with 
mitomycin-C treated OVA-loaded CMS5 with or without RAP expression. After 3 days, the draining inguinal and 
axillary lymph nodes were harvested and stained for CD45.2 and CD8 expression to differentiate adoptively 
transferred OT-1 cells from endogenous responses. (B and C) Histograms from the flow cytometry analysis of gated 
CD45.2+CD8+ OT-1 cells from representative mice of each group. (D) The percentages of dividing OT-1 cells were 
compared in mice immunized with OVA-loaded CMS5 cells, expressing RAP or control protein. * P < 0.05. 
Experiments were independently performed twice with 3-5 mice per group. Error bars indicated s.e.m. 
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Figure 3-10 Cross-presentation is abrogated in CD91-/- mice 
 (A) CFSE-labeled OT-1 cells were adoptively transferred into CD91-/- mice followed by immunization with 
replication incompetent, ovalbumin loaded CMS5 cells one day later. The CMS5 cells expressed RAP or an 
irrelevant protein. On day 3, lymph nodes were harvested and stained for CD8. (B-C) Representative histograms for 
CFSE on CD8+ cells is shown.  (D) the percentage of OT-1 cells that are dividing is shown. Error bars indicate 
s.e.m. 
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Figure 3-11 The effect of RAP on T cell proliferation is abrogated when mice are immunized with high dose 
OVA-loaded tumor cells 
 (A) CFSE-labeled CD45.2+ OT-1 cells were adoptively transferred into CD45.1+ C57BL/6 mice, one day before 
immunization with high dose (1x106 cells) of mitomycin-C treated OVA-loaded CMS5 with or without RAP 
expression. Three days post immunization, the draining inguinal and axillary lymph nodes were harvested and 
stained for CD45.2 and CD8 expression to differentiate adoptively transferred OT-1 cells from endogenous 
responses. (B) The percentages of dividing OT-1 cells were compared in mice immunized with OVA-loaded CMS5 
cells, expressing RAP or control protein. n.s. not significant. Experiments were performed with 3-4 mice per group. 
Error bars indicated s.e.m. 
3.4 DICUSSION 
In this chapter, I directly examine the requirement of ligand-binding ability of CD91 in mounting 
substantial immune resistance to tumors by utilizing molecules known to inhibit binding of 
ligands to CD91, such as RAP. The result demonstrated that tumors expressing RAP exhibited 
the same phenotype of decreased anti-tumor immunity as shown in CD91-/- mice. 
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Instead of wild type RAP that resides in the ER as an escort protein for CD91, a cytosolic 
version of RAP that lacks N-terminal signal sequence was transfected to tumors. Thus it allowed 
us to study the effect of elevated RAP levels on tumor immunogenicity even if only plasma 
membrane, but not ER membrane, was compromised in some physiological setting. However as 
a caveat, several post-translational modifications that normally occur in the lumen of ER/Golgi 
complex, such as forming of disulfide bonds and glycosylation, may be impaired in the cytosolic 
version of RAP. It may ultimately affect conformation of RAP and its binding to CD91. 
Although no disulfide bonds are possible for the sequence of RAP, it does have a sole 
glycosylation site (McCormick et al., 2005). However, previous study in our lab demonstrated 
that recombinant RAP lacking glycosylation can still inhibit binding of HSPs to CD91 in vitro 
(Binder and Srivastava, 2004). Additionally, the cytosolic RAP molecules used in this project 
were shown to decrease tumor immunogenicity, further negating the concern that lack of 
glycosylation in the RAP may inhibit its interaction with CD91. 
Tumors expressing RAP grew with significantly faster kinetics than the control protein- 
expressing counterparts in wild type mice. The control protein used was E.coli LacZ, as 
described in the methods section. LacZ did not contribute to immunogenicity because tumor cells 
expressing this protein grew with identical kinetics as untransfected cells (data not shown). 
Interestingly, the difference observed in wild type mice was non-existent in rag1/2-/- 
immunocompromised mice, corroborating the effect of RAP transfection on tumor 
immunogenicity, instead of the inherent proliferation rate of tumors. Most likely, RAP inhibited 
priming of the adaptive immunity, characterized by T cell responses which are the primary cell 
type responsible for tumor rejection (Boon et al., 1994; North, 1984; Udono et al., 1994). 
However, innate immune response may be dampened by RAP as well, since Rag1/2-/- mice not 
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only lack T/B cells, but also NKT cells. It is thus conceivable that NKT cells may be involved in 
HSP-mediated immune response. By using the NKT knockout mice (J(alpha)281(-/-)mice), we 
can examine the involvement of NKT cells in HSP-mediated immunity in the future. In addition, 
RAP-expressing tumors grew faster than non-RAP expressing counterparts, at early time points 
post tumor inoculation (e.g. day1 for SVB6). However, the tumor growth in rag1/2-/- mice was 
not measured between day 0 to day 4. These early time points may contain important information 
about the role of RAP on HSP-mediated innate immune responses, which may curb tumor 
growth before establishment of adaptive immunity. 
To validate the generality of the effect of RAP on tumor immunogenicity, a second line 
of tumor cells was used in this project---SVB6, which is a highly immunogenic regressor tumor. 
The T-antigen (Tag), the antigenic epitope of SVB6, cause the regression of SVB6 regardless of 
the dose of inoculation, which is similar to other T Ag expressing tumor studied previously 
(Chapes and Gooding, 1985). The immune response against T-antigen is presumably T cell-
mediated. Previous studies showed that substitutions in four T cell epitopes would compromise T 
cell receptor recognition (Lill et al., 1992). Also, induction of CTLs directed against these Tag 
epitopes might control Tag-induced tumors (Schell et al., 1999). Despite the high 
immunogenicity of parental tumor cells, RAP-expressing SVB6 tumors grew to a significantly 
bigger size and were rejected more slowly than control SVB6 tumor cells in immunocompetent 
mice. In immunocompromised rag2-/- mice, however, the growth of tumors was comparable 
irrespective of RAP expression until day 11, with the SVB6-Control cells growing faster than the 
SVB6-RAP thereafter. It further enhanced the validity of my conclusion.  
RAP-expressing cells, when used as immunogen in a prophylaxis assay (especially at low 
dose), were significantly less efficient in priming immune responses. It suggests that HSP-CD91 
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pathway is important very early in tumorigenesis. This phenomenon is echoed in T cell 
proliferation assay (Figure 3-11). It has been shown that depletion of CD8+, but not CD4+ T cells 
in the priming phase abrogates immunity elicited by gp96 (Udono et al., 1994). But it is unclear, 
in my system, which subset of T cells was affected by RAP during the priming phase. Therefore 
future studies will examine the involvement of CD4 and/or CD8 T cells in the same prophylaxis 
assay, by using anti-CD4 and/or anti-CD8 antibody to deplete CD4/8 T cells. 
When antigen is abundant, acquisition of antigens by APCs for cross-presentation and 
cross-priming can occur through several mechanisms which are prominent in infectious disease 
settings (Yewdell et al., 1999). These mechanisms are less reliant on the source of antigen or the 
type of APC (Norbury et al., 2004). Majority of tumor rejection antigens however derive from 
mutations of self proteins and so are estimated to be limited in quantity at the time of initiation of 
tumor-associated immunity (Srivastava and Srivastava, 2009). As previously demonstrated for 
transplantable tumors, concomitant immunity is established by day 3 when intradermal tumors 
are barely visible (North and Kirstein, 1977). A careful quantification and titration of the amount 
of antigen in tumors available for cross-presentation at this early stage is ~6 orders of magnitude 
less than is required if the antigen is transferred as a whole protein (Binder and Srivastava, 
2005). This necessitates a special mechanism to efficiently transfer antigens from the bearing 
(tumor) cell to the cross-presenting cell. Here I show that the HSP-peptide complex with its 
receptor CD91 provides such a mechanism. This study is supported by a large body of work in 
vitro demonstrating the efficient cross-presentation HSP-chaperoned peptides by a variety of 
CD91 expressing APCs (Binder, 2009; Binder et al., 2007; Blachere et al., 1997; Matsutake et 
al., 2010; SenGupta et al., 2004; Suto and Srivastava, 1995). Future studies will quantify the 
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amount of its immunodominant epitope (a mutated form of ERK2 protein in this case) (Ikeda et 
al., 1997) from titrated dose of CMS5 cells by western blotting or Mass spectrometry. 
Under physiological conditions, majority of RAP resides within the ER. Soon after the 
biosynthesis of LRP, RAP associates with the receptor and initiates the formation of multi-
molecular aggregates. Within these aggregates LRP is inactive in ligand binding. Following their 
trafficking together to the medial-Golgi compartment, RAP dissociates from LRP as a result of 
the low pH (-6.4-6.6) within the Golgi compartment (Bu et al., 1995; Chanat and Huttner, 1991). 
Intriguingly, because of increased glucose metabolism and poor perfusion, H+ production and 
excretion are generally increased in cancers (Schornack and Gillies, 2003), resulting in an acidic 
extracellular pH in solid tumors (pH 6.5–6.9) compared with normal tissue (pH 7.2–7.4)(Estrella 
et al., 2013; Gillies et al., 1994; Stubbs et al., 2000; van Sluis et al., 1999). Therefore, 
extracellular RAP may gradually dissociate from CD91 as solidly established tumors grow larger 
and generate a lower pH environment.  
I also tested ability of RAP to prevent antigen transfer and confirmed the importance of 
CD91 pathway when the amount of antigen is limited; on the nanogram level in the experiment 
shown in Figure 3-9 (The loading efficiency has been shown in Figure 3-8). It explains why the 
percentage of OT1 proliferation in response to OVA loaded cells was relatively small. I can 
easily incorporate supraphysiological amounts of antigen (microgram to milligram levels into the 
system and obtain stronger OT1 proliferation presumably as has been done by many others) 
(Quah et al., 2007). Obtaining ‘strong’ OT1 proliferation, typically achieved with 
supraphysiological amounts of antigen, is not a goal of this thesis project. This issue is also 
negated by the fact that T cell responses are sufficient to slow down growth of tumors as shown 
in Figure 2-5, Figure 3-4 and Figure 3-7. 
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4.0  CD91 IS REQUIRED FOR UPTAKE OF IMMUNOGENIC HSPS AND 
TRANSFER OF ANTIGEN 
4.1 RATIONALE 
The form of antigens that are transferred from tumor cells or infected cells to APCs to prime 
downstream immune responses has been a longstanding debate. Several possible forms of 
antigen include intact proteins, free peptides derived from protein, peptides presented by MHC 
class I molecules (as a part of the process of cross-dressing), or chaperoned by HSPs. Among 
them, peptides chaperoned by HSPs has been shown to be necessary and sufficient for cross-
prime of CD8+ T cells. Indeed, tumor cell lysates in which four major immunogenic HSPs were 
depleted can no longer elicit downstream T cell responses. Addition of either one of these HSPs 
restored the activity.  
However, depletion of intact antigenic proteins did not abrogate the immunogenic 
activity of tumor cell lysates. In addition, the efficiency of intact protein to prime T cell 
responses is much lower than peptides chaperoned by HSPs. Six orders of magnitude higher 
amount of intact protein is required to elicit immune response as robustly as that mounted by 
HSP-peptide complexes. High efficiency of antigen transfer is particularly relevant during the 
early development of tumor when antigen dose is limited.  
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With regard to peptides derived from protein, several pieces of evidence showed that they 
cannot exist in their free form: (1) free peptides are too small to assume secondary and tertiary 
structures necessary to shield hydrophobic residues; (2) A robust search for free peptides in cells 
found none (Menoret et al., 1999); (3) The high efficiency of antigen processing and presentation 
indicates that random peptide diffusion is not an option. Indeed, degradation of only 30-5000 
proteins are needed for each peptide presented on MHC I (Finelli et al., 1999; Yewdell, 2001).    
Peptides presented by MHC class I molecules may serve as another form of antigen 
transferred for cross-dressing, a process in which intact cell-surface proteins (MHC-peptide 
complexes in this case) are rapidly exchanged between cells that are in contact with each other. 
However, cross-dressing may have a significant role only in activating previously primed CD8+ 
T cells, but not naive T cells (Wakim and Bevan, 2011). Therefore, this process may have 
minimal, if any, role in transferring antigen from nascent tumors to APCs. 
As shown in the previous chapter, the ligand-binding ability of CD91 is required for anti-
tumor immune responses. However, the identity of immunogenic ligand(s) that are impacted by 
the deficiency or blockade of CD91 is unknown.  Since HSPs-chaperoned peptides are both the 
necessary and sufficient form of antigen transferred from tumor cells to APCs, I designed 
experiments in this chapter to dissect the role of CD91 on uptake of HSPs. I utilized a strategy to 
label HSP gp96 with Enhanced Green Fluorescent Protein (EGFP) and co-transfected gp96-
EGFP with RAP or a control protein into different tumor cells (Figure 4-1). The localization and 
trafficking of this fluorescent-labeled gp96 was then monitored in vivo. My general hypothesis is 
that RAP would compete away gp96-EGFP from binding to CD91, and hence reduce EGFP-
derived green signal detected on immune cells in the draining lymph nodes.  
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Figure 4-1. Strategy to examine uptake of HSPs in vivo 
CMS5 cells were constructed to express gp96-EGFP, simultaneously with either RAP or control protein, in order to 
examine the role of RAP on HSP transfer to APCs. I hypothesized that RAP inhibits APCs from taking up tumor-
derived EGFP-labeled HSPs in draining lymph nodes. 
4.2 MATERIALS AND METHODS 
4.2.1 Cells and reagents 
Double transfected tumor cells (gp96EGFP+RAP, or gp96EGFP+control vector) were cultured 
in complete DMEM media plus blasticidin (3µg/mL, Invitrogen) and geneticin (0.7g/L, GIBCO). 
APC anti-CD45 antibody was purchased from Invitrogen (Carlsbad, CA). Anti-grp94 antibody, 
anti-PDI antibody, anti-Hsc70 antibody were purchased from Enzo Life Sciences (Farmingdale, 
NY). Anti-EGFP antibody was purchased from Clontech (Living Colors Full-length A.V. 
polyclonal antibody) (Mountain View, CA) 
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4.2.2 Plasmid construction and transfection. 
 
Figure 4-2. Gp96-EGFP Construct Strategy 
The diagram illustrates the procedure to generate gp96-EGFP vector (Courtesy of Dr. Michelle Messmer) 
 
The gp96EGFP (C-terminal fusion protein) was generated by sequential RT-PCR and 
subcloning. The gp96 cDNA was amplified from murine RNA using an N-terminal primer 
upstream of the gp96 start codon and a C-terminal primer with complementarity starting at 
nucleotide 2483, and the codons for KDEL, an ER retention signal sequence, and the stop codon 
were replaced with an NdeI restriction cut site. This construct was inserted into the pEF6/V5-
His-TOPO vector and orientation was confirmed by restriction enzyme digestion and sequencing 
analysis. EGFP was prepared via 2-step PCR. First, EGFP cDNA was amplified from a 
commercial vector (Invitrogen), using a complementary N-terminal primer and a complementary 
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C-terminal primer with an overhang for the KDEL and stop codons. EGFP was then reamplified 
using an N-terminal primer with an NdeI restriction site overhang and a C-terminal primer 
complementary to the C-terminus with KDEL and stop codons and with a NotI restriction site 
overhang. The final EGFP construct was ligated into the gp96 containing vector and the final 
product was fully sequenced to confirm the sequences were in frame and that no mutations 
occurred during this construct assembly process. CMS5 tumor cells were stably co-transfected 
with gp96-EGFP vector (with blasticidin resistent gene) and RAP/Control vector (with geneticin 
resistent gene), by using Fugene® 6 transfection reagent (Roche Molecular Biochemicals). 
4.2.3 HSP transfer experiments in vivo.  
5x106 CMS5 cells co-transfected with RAP and gp96-EGFP, or CMS5 co-transfected with 
control vector and gp96-EGFP, were injected in one footpad of wild type BALB/c or CD91-/- 
mice. Two days later, the draining (dLN) and contra lateral (non-draining, ndLN) popliteal 
lymph nodes were harvested. EGFP signal in CD45+ cells in the lymph nodes were compared. 
Due to minor variations in auto-fluorescence observed in each mouse and in fluorescence of the 
gp96-EGFP expressing cultured cells over time, the signal was normalized to these two 
parameters by accounting for background signal in contralateral (ndLN) popliteal lymph nodes 
and fluorescence of gp96-EGFP expressing cells on the day of the experiment respectively 
(Figure 4-5 C-D; Table 4-1; Table 4-2). The following formula was used: 
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4.2.4 Statistical analysis.  
An unpaired two-tailed Student's t-test or two-way ANOVA test was used for statistical analyses, 
and a P value of less than 0.05 was considered statistically significant. Error bars were calculated 
as standard error of the mean (s.e.m). 
 
4.3 RESULTS 
CD91 is required for uptake of immunogenic HSPs 
To determine whether CD91 was essential for HSP-peptide cross-presentation in vivo, an assay 
was developed to monitor HSP transfer to APCs and the localization of the HSP in the lymph 
node. CMS5 cells were constructed to express gp96-EGFP, simultaneously with either RAP or 
control protein (Figure 4-1). Examined by Coomassie stain (Figure 4-3 A), immunoblot (Figure 
4-3 B), and confocal microscopy (Figure 4-3 E), gp96-EGFP was expressed robustly at roughly 
the same level as endogenous gp96. It was expressed in the ER (as indicated by co-localization 
with PDI), but not in the cytosol (as indicated by absence of co-localization with Hsc70) (Figure 
4-3 C-D). 
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Figure 4-3. Robust expression of gp96-EGFP in transfected CMS5 
(A-B) Gp96 was purified from transfected CMS5 cells by using previously described method. Two fractions of 
elution buffer from the DEAE column were loaded in a 10% SDS-PAGE gel, separated by electrophoresis, and 
stained with Coomassie Blue. Proteins on the gel were then transferred to an Immobilon-P membrane, blotted with 
anti-gp96 or anti-EGFP antibodies, and developed in a X-ray film. The gel (A) and film (B) was imaged with the 
Kodak Image Station. (C-E). Robust fluorescence of gp96-EGFP was analyzed by confocal microscopy. Gp96-
EGFP transfected CMS5 cells were labeled with: (C) Hoechst staining for nuclei, Phalloidin staining for 
cytoskeleton, and anti-PDI antibody staining for ER; or (D) Hoechst staining for nuclei, Phalloidin staining for 
cytoskeleton, and anti-hsc70 antibody staining for cytosol; or (E) DAPI staining for nuclei and Phalloidin staining 
for cytoskeleton. (Data from Dr. Michelle Messmer) 
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Figure 4-4. Experiment design and multiple scenarios for HSPs trafficking 
(A) CMS5 tumor cells co-transfected with gp96-EGFP/RAP or gp96-EGFP/Control protein were inoculated into one 
footpad of mouse. Two days later, both draining and non-draining popliteal lymph nodes were collected for analysis; 
(B) Schema for possible routes of HSPs trafficking from tumor cells in peripheral tissue to draining lymph node. (1) 
HSPs released from tumor microenvironment can be passively drained to lymph node and taken up there by the LN-
resident APCs; (2) HSPs, once released from tumor cells, can be immediately taken up by peripheral APCs. Those 
peripheral APCs are then migrated to draining lymph node; (3) apoptotic tumor cells can be directly transferred to 
draining lymph node. (Courtesy of Dr. Michelle Messmer) 
 
The two tumor types were implanted into individual foot pads of BALB/c mice and 
draining lymph nodes were harvested 2 days later (Figure 4-4 A). The popliteal lymph node cells 
were stained and gated on CD45 to identify hematopoietic cells and exclude tumor cells that 
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potentially drained directly, from the analysis (Figure 4-4 B; Figure 4-5 B). The amount of EGFP 
fluorescence was measured by flow cytometry (Figure 4-5 C-D). Due to minor variations in 
auto-fluorescence observed in each mouse and in fluorescence of the gp96-EGFP expressing 
cultured cells (Figure 4-5 A), the signal was normalized to these two parameters by  accounting 
for background signal in contralateral (non-draining) popliteal lymph nodes and fluorescence of 
gp96-EGFP expressing cells on the day of the experiment respectively (Figure 4-5 C-D; Table 
4-1; Table 4-2). Significantly less EGFP was detected in lymph nodes when tumors expressed 
RAP compared to control protein (P = 0.0002, Figure 4-6 A).  
I tested the transfer of HSP to APCs in CD91-/- mice using the same system. CMS5 cells 
expressing gp96-EGFP with or without RAP were implanted in the footpads of CD91-/- mice. 
Draining lymph node cells were harvested after 2 days and analyzed as in Figure 4-6 A. As 
shown in Figure 4-6 B, I did not detect gp96-EGFP signal in the lymph node regardless of 
whether cells expressed RAP or not. The importance of CD91 for HSP transfer and trafficking is 
thus highlighted in cases of deficient expression in APCs and antagonism via RAP.  
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Figure 4-5. Transfer of tumor-derived gp96 to lymph node cells in vivo. 
CMS5 cells expressing RAP or control protein were transfected with gp96-EGFP. (A) Robust fluorescence of gp96-
EGFP was analyzed by flow cytometry. (B) Following implantation of cells into the foot pad of BALB/c mice, 
draining lymph nodes were isolated and stained for lymphocytic marker CD45 and analzed by flow cytometry for 
EGFP as shown in Figure 6. A representative plot shows the CD45 gated population. (C and D) Representative 
histogram shows the EGFP-containing CD45+ cells in the non-draining lymph node (ndLN) or draining lymph node 
(dLN) following implantation of CMS5 cells expressing gp96-EGFP, and RAP or an irrelevant protein, into BALB/c 
(C) or CD91-/- (D) mice. 
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Table 4-1. MFI of all BALB/c mice from HSP transfer experiment in vivo 
MFI of all BALB/c mice from one experiment are shown. Denominator is the MFI (CMS5-EGFP before 
implantation) - MFI (untransfected CMS5 before implantation). These numbers are imported into the formula 
described in the Materials and Methods to obtain the normalized signal. 
 
Table 4-2. MFI of all CD91-/- mice from HSP transfer experiment in vivo 
MFI of all CD91-/- mice from one experiment are shown. Denominator is the MFI (CMS5-EGFP before 
implantation) - MFI (untransfected CMS5 before implantation). These numbers are imported into the formula 
described in the Materials and Methods to obtain the normalized signal. 
 
 
 
Figure 4-6. Transfer of HSP-peptide complexes to APCs requires engagement of CD91 
CMS5 cells expressing RAP or control protein were transfected with gp96-EGFP. The foot pad of BALB/c (A), or 
CD91-/- (B), mice were implanted with 5x106 of either cell type and the draining or contralateral non-draining lymph 
nodes were harvested two days later. Cells were stained for the hematopoietic marker CD45 and analyzed by flow 
cytometry for EGFP. The EGFP signal was normalized against the starting fluorescence in each cell type and the 
background fluorescence of non-draining lymph nodes. *** P < 0.001, n.s. not significant. Experiments were 
independently performed twice with 8 mice per group (A), or 3 mice per group (B). Error bars indicated s.e.m. 
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4.4 DISCUSSION 
In this chapter, I studied the requirement of CD91 for uptake of immunogenic HSPs, by tracking 
localization of fluorescent-labeled gp96 in the draining lymph nodes. In the presence of RAP, 
less fluorescence was detected on CD45+ immune cells in draining lymph nodes. When CD91-/- 
mice were used, however, HSPs were not taken up by any CD45+ lymph nodes cells regardless 
of RAP expression by tumor cells. The implication for this data is two-fold: (1) it suggested that 
HSP is the molecule that RAP inhibits from binding to CD91 as shown in previous chapter; (2) it 
supported the importance of CD91 (in CD11c+ cells) on HSP trafficking and antigen transfer in 
vivo.  
GFP-gp96 is expressed at similar level as endogenous gp96, as shown in the Figure 4-3 
A-B. As with the previous chapter, my goal is not to simply present responses with 
supraphysiological conditions, but to create a system to mimic as close as technically possible to 
what is physiologically relevant. Therefore, the expression level of gp96-EGFP in cell clones 
that I chose is close to endogenous levels, and even decreases with passage (data not shown). 
Similar to endogenous gp96, the transfected gp96-EGFP protein has an ER retention signal, 
KDEL, on its C-terminal end. Retention of those proteins in the lumen of ER is achieved by their 
continual retrieval from the cis-Golgi or a pre-Golgi compartment. This process is mediated by a 
receptor (e.g. KDELR1) that recognizes and binds the KDEL-containing protein and then returns 
it to the ER (Pelham, 1990). A possible reason why expression level of gp96-EGFP decreased 
with passage is that robustly expressed gp96-EGFP exceeds the capacity of those KDEL 
receptors, so that any excess proteins can escape the ER retention and be secreted into the 
extracellular environment. To examine this possibility, the amount of extracellular gp96-EGFP 
in the supernatant of cell culture can be measured by western blotting. 
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Harvesting lymph nodes 48 hours after tumor injection was a decision made based on my 
preliminary data. When lymph nodes were harvested 72 hrs after injection, RAP had no effect on 
HSP uptake (data not shown).  At those time points, many other factors such as antigen 
destruction, aggregation and phagocytosis come into play as previously described (Delamarre et 
al., 2005). Considering the fact that (i) majority of antigen is destroyed by the expressing cells, 
(ii) destroyed in the extracellular environment, (iii) APCs that can take up antigen account for 
~0.1% of the total lymph node population (Itano et al., 2003; Messmer et al., 2013), the amount 
of antigen that I detect is certainly meaningful, if not excellent. 
Future studies will examine and identify APC subsets that take up gp96-EGFP in vivo. In 
addition, studying sorted APC with gp96-EGFP in vitro may provide a hint. However, one 
caveat is that some APC subsets that are capable to bind to gp96-EGFP in vitro may not be able 
to access and interact with the same antigen in vivo, due to anatomical limitation.  
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5.0  CONCLUSIONS, SIGNIFICANCE AND FUTURE DIRECTIONS 
Adaptive immune responses against tumors are routinely detected in hosts bearing the tumor due 
to immunosurveillance mechanisms. How the immune response to tumors is initially primed 
remains unclear, given the limited amount of tumor antigen available for cross-priming and lack 
of classical pathogen associated molecular patterns (PAMPs). I demonstrated in this dissertation 
that specific ablation of CD91 in antigen presenting cells prevented the establishment of anti-
tumor immunity, especially early in tumor development. Anti-tumor immunity was also inhibited 
when transfer of tumor-derived HSPs to APCs was prevented by using RAP, an endogenous 
inhibitor of CD91. Inhibition was manifested in a reduction of cross-presentation of tumor-
derived antigenic peptides in lymph nodes.  
Following priming of anti-tumor immunity, a period called immune-editing occurs where 
tumors may develop several mechanisms allowing for co-existence with the immune response 
(DuPage et al., 2012; Matsushita et al., 2012; Schreiber et al., 2011). These mechanisms include 
induction of immunosuppressive factors, activation of regulatory cells, loss of antigen 
expression, or tumor-induced impairment of antigen presentation. As a mechanism of evasion of 
the immune response by tumors, preceding or at the early stage of immuno-editing, I hypothesize 
that tumors may over-express RAP, or other as yet undiscovered endogenous CD91 inhibitors, to 
disrupt HSP-CD91 pathway and impair antigen transfer. Interestingly, a previous study identified 
a positive correlation between elevated RAP levels and progressive disease in colon cancer 
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patients (Sakamoto et al., 2011). I expect this mechanism to occur during initiation of tumors to 
allow the tumors to be firmly established, because antigen burden is very low, and HSP-mediated 
antigen uptake prevails at this stage. 
 
 
Figure 5-1. Model: Evasion from Immunosurveillance/ Elimination 
Schema for the three 'E's model of cancer immunoediting, which consists of three stages of interactions between 
cancer cells and immune system: (1) Elimination; (2) Equilibrium; and (3) Escape. It shows how the conclusions 
from this thesis fits into the model. [Figure adapted from (Dunn et al., 2004)] 
 
I note that as tumor grows and tumor antigen becomes more abundant, other mechanisms 
of antigen transfer and T cell priming may be evoked, so that the inhibitory effect of RAP on 
antigen transfer is abrogated. This is hinted at in Figure 3-7, when mice are immunized with 
larger cell numbers (>100,000). These other mechanisms of antigen transfer may become 
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dominant in cases of over-expressed self or oncoviral tumor antigens, which may [supported by 
our own work, (Binder and Srivastava, 2005)] or may not be via HSP-mediated processes 
[supported by work from other labs, (Norbury et al., 2004; Yewdell et al., 1999)]. Besides HSPs 
released in the extracellular environment after necrotic death of tumor cells, there are several 
other means that are possible to transfer HSPs to the surrounding APCs. For example, some 
cancer chemotherapeutic treatments, such as anthracyclins, induced apoptotic death of cancer 
cells. While apoptosis imposes a silence signal on immune system in traditional view, the one 
generated by these chemotherapy agents however can foster a favorable immunogenic 
environment. Interestingly, the reason behind the phenomenon was that anthracyclins or similar 
agents induced rapid translocation of an intracellular HSP calreticulin (CRT) to the cell surface 
of tumors prior to apoptosis, which facilitated phagocytosis of dying tumors (Obeid et al., 2007a; 
Obeid et al., 2007b). The ability of cell surface CRT to enhance phagocytosis may be correlated 
with the intrinsic feature of CRT to serve as a binding ligand for receptors on APCs, such as 
CD91 (Gardai et al., 2005). The exposed HSPs may also be taken up by other receptors than 
CD91, some of which were mentioned in the chapter 1.3.2. Besides the apoptosis-induced 
exposure on cell surface, HSPs may also get access to extracellular environment in the form of 
exosomes. A study in vitro demonstrated that exosomes produced by B-lymphoblastoid cell lines 
under stress condition contained hsp27, hsc70, hsp70, and hsp90. Although this study showed 
that the exosomes cannot induce direct activation of dendritic cells, they may serve as a vehicle 
to transport HSP-chaperoned antigens (Clayton et al., 2005). In another study, exosomes derived 
from resistant anticancer drugs-treated HepG2 cells conferred superior immunogenicity in 
eliciting HSPs-specific NK cell responses in vitro (Lv et al., 2012). However, the role of 
exosomes to deliver HSP in vivo remains unclear. Antigen may even be transfer without the aid 
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of HSP molecules, in the form of whole proteins, although whole protein is cross-presented 
extremely inefficiently, and even absent unless used at supraphysiological amounts (Basta et al., 
2005; Blachere et al., 2005; Li et al., 2001).  In addition, nucleic acid can be another form of 
tumor antigen. Studies showed that murine DCs transfected with mRNA amplified from the B16 
melanoma cells elicited potent CD8+ T cell responses, which led to the regression of metastasis 
in tumor-bearing mice (Boczkowski et al., 2000; Gilboa and Vieweg, 2004). However, the 
relevance of mRNA in vivo as an effective form of antigen transferred from tumor cells to APCs 
remains to be examined. As a follow-up, we plan to explore these possible mechanisms that 
obviate the requirement of CD91 pathway when antigen is abundant. 
The loss of effect of RAP at high dose of immunization could also be attributed to the 
generation of acidic extracellular environment as tumor grows larger (Estrella et al., 2013; 
Gillies et al., 1994; Stubbs et al., 2000; van Sluis et al., 1999). Indeed, previous studies showed 
that RAP binds to CD91 with high affinity to serve as an escort protein along the secretion 
pathway of CD91 until it reaches the medial-Golgi compartment, where it then dissociates from 
LRP due to the low pH (-6.4-6.6) within the Golgi compartment (Bu et al., 1995; Chanat and 
Huttner, 1991). Similarly, RAP may dissociate from CD91 in an acidic environment within 
established tumors, and normal uptake of HSP-peptide complexes via CD91 can therefore be 
resumed. However, tumor cells can also take advantage of the acidic environment thereafter, 
since acidity may be toxic to normal cells and inhibit the immune response to tumor antigens 
(Gatenby et al., 2006; Lardner, 2001). In contrast, cancer cells develop mechanisms that allow 
them to survive in acidic environments (Wojtkowiak et al., 2012). 
The mechanism of immune evasion by disrupting CD91 pathway may also impact cancer 
metastasis. In the conventional model of cancer progression, metastasis is viewed as a sequential 
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multistep process (Chambers et al., 2002; Chiang and Massague, 2008). By gradually acquiring 
the ability to invade, tumor cells at the primary sites are disseminated into the systemic 
circulation. Shedding of tumor cells into circulation may occur in large numbers even at early 
stages of cancer, which contributes to the spread of cancer to distant organs (Husemann et al., 
2008; Stoecklein et al., 2008). But only a few circulating cells form overt metastasis. Some 
examples of impediments to the formation of metastasis includes tight vascular barriers, rare 
acquisition of organ colonization function, unfavorable microenvironment for survival and 
immunosurveillance at distant organs (Nguyen et al., 2009). However, cancer cells may develop 
a variety of mechanisms to adapt to these difficult scenarios. As in the primary sites, limited 
amount of CTCs expressing RAP or other competing ligands for immune receptors may also 
gain huge advantage to allow them firmly established at distant organs. 
I have used transplantable tumors in these studies because by doing so, I can carefully 
titrate the input of tumors into mice, measure antigen-specific immune responses and stably 
introduce CD91 inhibitors such as RAP into the tumors. However, the role of CD91 in de novo 
induction of tumors remains to be tested, as was performed for the dependence of anti-tumor 
immunity on IFN-γ (Shankaran et al., 2001). I am currently investigating carcinogen- and UV- 
induction of tumors in CD91-/- mice. Cohorts of age-matched CD91-/- mice and CD91+/+ 
littermates will be injected with methlycholanthrene (MCA, dissolved in peanut oil, SIGMA) and 
will be monitored every week for development of palpable tumors. IFNrR-/- mice will be used as 
controls. In addition, the KP murine model (developed by Tyler Jacks and available in Jackson 
Labs) will be used to measure immunosurveillance to spontaneous tumors. Tumor suppressor 
gene p53 can be deleted and oncogene K-rasG12D can be expressed in these mice under the 
inducible Cre/LoxP system, by intramuscular injection of viral vectors expressing Cre 
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recombinase. This system has a unique advantage over the chemically induced system (Aim 1.1), 
because a specific tumor antigen can be introduced by incorporating the antigen into the vectors 
alongside Cre recombinase. We plan to make bone marrow chimeras such that the KP mice lack 
expression of CD91 in CD11c+ cells. These studies will allow us to study the role of CD91 in the 
very early phase of de-novo tumorigenesis. The immunogenicity of these de-novo tumors can 
also be sculpted by the immune system. Tumors that are established in CD91-/- mice, and 
harvested at <6-8 days, are expected to be more immunogenic and rejected faster when 
transplanted into wild type mice, when compared to tumors established in wild type mice and 
transplanted into wild type mice. I expect this because those early tumors established in CD91-/- 
mice are presumed to be less edited, if edited at all, due to a failure in the establishment of anti-
tumor immunity in these mice. 
The impact of the loss of expression of CD91 in CD11c+ cells also raises several other 
issues; first, CD91 is known to bind to other ligands (Herz and Strickland, 2001). However, of 
these ligands, only α2M has been shown to have any immunological function (Binder et al., 
2001; Chu and Pizzo, 1993). Thus, although not tested here, α2M bound to extracellular tumor 
antigens may be another mechanism for cross-priming. Second, it is important to clarify that the 
endocytosis of HSPs may not be the only critical feature of HSP-mediated immunity that is 
disrupted in our CD91-/- mice. Deficiency of HSP signaling through CD91 on CD11c+ cells can 
abrogate maturation of those APCs, which ultimately reduce effective priming as well. To 
investigate the adjuvant effect of HSP-CD91 pathway, peptide-binding site of HSPs or the 
tyrosine phosphorylation (NPXY) motifs on the cytoplasmic tail of CD91 will be mutated, and 
its effect on NF-kB translocation, cytokine secretion, and rate of tumor growth will be assessed. 
In addition, infiltration of innate immune cells in tumor microenvironment will be examined, 
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especially in the early time points after inoculation of tumors. Third, in this study, I only 
examined a prototypic HSP, gp96. However, as our lab has already shown, other types of 
purified HSPs give rise to different immune outcomes following CD91 engagement.  It is 
therefore important to investigate the relative contribution of each HSP known to bind CD91 to 
the global immune response. Fourth, given the recent observation that CD169+ macrophages are 
bona fide professional antigen presenting cells in the setting of apoptotic-associated antigen in 
lymph nodes (Asano et al., 2011), I expect a more robust phenotype when CD91 expression is 
eliminated in both macrophages and dendritic cells. Additionally, the expression of CD91 in 
different APC subsets has been examined and published recently by our lab (Messmer et al., 
2013). Those studies examined APCs subsets from the lymph node in vivo. Among different 
APC subsets, CD91 is most highly expressed on CD11c+CD11b+ cells, which correlates with 
their superior capacity to uptake. Other CD11c populations express lower CD91 levels. 
Therefore, studies are currently underway to create mice with loss of CD91 in both CD11c+ and 
CD11b+ cells. Fifth, it is recently shown that a spontaneous CD8+ T cell response against 
transplantable tumors depends on host type I IFN signaling (Gajewski et al., 2012; Gajewski et 
al., 2013). Gene expression profiling in these studies revealed that tumors having high expression 
of T-cell markers also exhibit a type I IFN transcriptional signature (Harlin et al., 2009). 
However, the link between type-I IFN pathway and HSP-CD91 pathway is still unknown, as 
these two pathways may complement, inhibit or supersede each other. 
The findings in this study may also have a bearing on prognosis of immunotherapy 
against cancer. If the absence of T cells is due to the expression of endogenous CD91 inhibitors 
by cancer cells, a prevalent approach for adoptive T cell transfer could then be deployed, which 
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involves isolation of tumor specific T cells from blood of patients, expanding them in vitro and 
re-infusing these autologous, in vitro expanded T cells back into the patient (Ho et al., 2002).  
In summary, the data from this dissertation describes a novel molecular mechanism for 
antigen transfer during tumor immunosurveillance. I show that disrupting HSP-CD91 pathway 
abrogates tumor-associated immunity. This pathway is important very early in tumorigenesis, 
when antigen load is low. Based on these findings, I propose a novel mechanism of immune 
evasion for tumors expressing competing ligands for immune receptors such as CD91. A better 
understanding of these mechanisms will also guide us in designing immunotherapeutic 
approaches against malignant tumors. 
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